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ABSTRACT 
UDP-glucuronosyltransferase (UGT) 1A1 is a phase II enzyme. Epidemiological 
studies have associated UGT1A1 expression to breast cancer risk. It is suggested that 
increased UGT1A1 can metabolize estrogen and reduce the exposure. 
The objectives of the current study were to investigate the effect of over-expressing 
UGT1A1 on the assault of xenobiotics. 7,12-dimethylbenz[a]anthracene 
(DMBA)-DNA covalent binding and comet assay result demonstrated that 
over-expressing UGT1A1 could reduce DNA damage induced by xenobiotics. In 
addition, some responses to estrogen such as cell proliferation and estrogen receptor 
expression were suppressed by an elevated level of UGT1A1. 
Subsequently, real-time polymerase chain reaction (PCR) showed that 
phytochemicals such as resveratrol and genistein could suppress the mRNA 
expression of UGT1A1 in the presence of DMBA. The reduced level of UGT1A1 
was not desirable to the prevention of breast cancer; however, further assays revealed 
that suppressing UGT1A1 did not increase the damages on DNA. It appeared that 
suppression on CYP1A1 and CYP1B1 conferred the protective effect. 
Ill 
Increased UGT1A1 could be beneficial to prevent the initiation of cancer. As 
UGT1A1 represents a major phase II drug metabolizing enzyme, high expression 
might also intervene drug therapy. MTT assays showed that over-expressing 
UGT1A1 lowered the effectiveness on growth inhibition of tubulin-binding agents, 
i.e. paciltaxel and vincristine; but not of DNA-damaging agents, i.e. doxorubicin and 
methotrexate. Flow cytometry showed that paclitaxel and vincristine induced cell 
cycle arrest in wild-type cells, however, this cell arrest process was reduced in 
UGT1A1 -transfected cells. The underlying mechanism was not clear. 
Results of the current study illustrated that an elevated level of UGT1A1 might 
protect against breast cancer. Our lab previously demonstrated that genistein and 
resveratrol protects DNA damage. However, results of current study showed that 
genistein and resveratrol reduced the DNA damage induced by DMBA through an 
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CHAPTER 1. INTRODUCTION 
1.1 Breast Cancer 
Breast cancer is a common disease that women are suffering. There are two types of 
breast tumor, benign and malignant. The benign tumors cannot spread or threaten 
one's life while malignant tumors can spread throughout the body or invade tissues. 
Any types of tissue in the breast can be transformed, but cancers are usually found in 
the ducts or the glands. In Hong Kong, breast cancer has been the second most 
common female cancer since 1990，and it has accounted for almost 20% of all new 
female cancer cases. Figure 1.1 shows the distribution of new cancer cases among 
female in 2001. Besides, breast cancer is one of the leading causes of death among 
women population in the past few years (Hong Kong Anti-Cancer Society). 
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Source: Hong Kong Cancer Registry, Hospital Authority 
Fig. 1.1 Distribution of cancer new cases among female in Hong Kong, 2001. Breast 
cancer is the most common cancer among women in Hong Kong. (Source: 
Hong Kong Anti-Cancer Society) 
1.2 Development of Breast Cancer 
The development of carcinomas involves three stages: initiation, promotion and 
progression, and an interruption in any of the three stages could prevent cancer 
development. During the stage of initiation, exposure to chemical carcinogens 
generates reactive electrophilic intermediates. These reactive species interact with 
DNA and generate lesion on it. Normally, cells have repair systems to fix the lesion. 
However, once the number of lesfons overwhelms the cell's repair system or a 
2 
dysfunctional gene occurs in the system, mutations are unavoidable. The miscoded 
bases are passed onto the newly divided cells through DNA replication, and they are 
permanently incorporated in the gene sequences. The number of mutated cells 
increases in the promotion phase. This process is greatly accelerated in the presence 
of various growth factors. The preneoplastic cells then enter the progression stage, 
and gradually become neoplastic. Neoplastic cells have a growth pattern different 
from their neighbouring cells, and can either be benign or cancerous. Obviously, if 
we can lower the formation of reactive species in the initiation stage or reduce cell 
proliferation during the stage of promotion, the risk of tumor development will be 
decreased. 
1.3 Risk Factors of Breast Cancer 
Risk factors of breast cancer include age, genetic factors, hormonal factors and 
lifestyles as well. 
1.3.1 Age 
Table 1.1 shows the chances of developing breast cancer in different age groups of 
female population. The risk of developing breast cancer increases with women's age. 
About 77% of women with breast cancer are over age 50 at the time of diagnosis. 
3 
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Source: National Cancer Institute, 2004. 
Table 1.1 The incidence rate of breast cancer of different age groups. As women age, 
her risk of breast cancer also increases. 
1.3.2 Genetic Factors 
Genetic contributes about 10 percent of all breast cancer cases. Changes in certain 
genes can increase the risk of breast cancer. According to previous studies, 
Caucasian women have a higher risk to develop breast cancer than African-American 
women, though African-American women have the highest mortality rate 
(Ademuyiwa & Olopade, 2003). These differences may be due to racial disparities. 
Many genes, such as BRCA1 and BRCA2, HER-2, p53 tumor suppressor gene, 
CYP1A1 and UGT1A1, have been associated with breast cancer (Ademuyiwa & 
Olopade, 2003). BRCA1 and BRCA2 genes are involved in cellular processes in 
maintaining transcriptional regulation and genomic stability. According to a survey 
conducted by Imaginis Corporation, women with BRCA1 mutations account for 5% 
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of all breast cancer cases currently. Human epidermal growth factor receptor-2 
(HER-2) plays an important role in regulating cell growth. Mutation in this gene 
results in extra HER-2 receptors being produced. Over-expression of HER-2 causes 
increased cell growth and reproduction, often resulting in a more aggressive 
phenotype. According to the Imaginis survey, HER-2 protein over-expression affects . 
25% to 30% of breast cancer patients. Mutation in p53 tumor suppressor gene also 
increases breast cancer risk. Both CYP1A1 and UGT1A1 are drug-metabolizing 
enzymes. CYP1A1 is a phase I metabolizing enzyme, while UGT1A1 is a phase II 
metabolizing enzyme. Besides, CYP1A1 hydroxylates estrogen at the position ofC-2, 
and UGT1A1 glucuronidates estrogen at C-3. Mutation or polymorphism in these 
genes is associated with breast cancer risk (Ademuyiwa & Olopade, 2003). 
1.3.3 Hormonal Factors 
A prolonged exposure to estrogen is associated with increased risk for breast cancer 
(Key, 1999). Conditions such as post-menopausal obesity, the use of oral 
contraceptives, early menarche, late menopause, hormone replacement therapy and 
alcohol consumption increase the level of circulating estrogen and thus increase the 
risk of breast cancer. 
5 
1.3.4 Lifestyles 
Lifestyle is also associated with the risk of breast cancer. For example，a high fat diet 
and lack of exercises are associated with higher risk of breast cancer (Imaginis, 
2006). Lifestyle could be of greater importance to women who are prone to breast 
cancer development. 
1.4 Drug Metabolism 
Drug metabolism in cells involves 4 phases. In phase 0, lipophilic endo- and 
xenobiotic substrates enter cells by passive diffusion or uptake transporters. In phase 
I, the endo- and xenobiotics are converted into nucleophillic phenols and 
polyphenols or electrophiles, such as quinines and epoxides, which are then 
conjugated by phase II enzymes such as UGT. Finally, in phase III，the resulting 
organic anions are removed from the cells via export transporters (Bock, 2003). The 
balance between phase I and II enzymes often determines the accumulation of 
reactive intermediates which may cause oxidative or electrophilic stress and toxicity. 
The latter is initiated by covalent binding of metabolites to DNA, forming 
DNA-adducts. Fig. 1.2 illustrates the drug metabolic pathway. 
6 
Promotion Progression 
Initiation (PosMnftjatiort} (Malignant corwerskxi) 
DNA damage 、嘛 ^ ^ ^ ^ 
Normal cells 个 Mutant cells Benign tumors Maligrtantlumors 
% v'a- ^ i r f Detoxification/ 
"^.-Activationof ! ^ inactivauon ——• increased 
Procarcinogens by CYPs- ^ phase II enzymes 
elimination 
Fig. 1.2 Phase I and phase II enzyme reactions involved in biotransformation. 
Carcinogen activation is inhibited by controlling the balance between 
carcinogen-activating phase I enzymes and phase II detoxifying enzymes. 
(Modified from (Moon et al., 2006) 
1.5 UGT1A1 
1.5.1 UDP-glucuronosyltransferases 
UDP-glucuronosyltransferases (UGTs) represent a major class of phase II drug 
metabolizing enzymes. They are membrane-bound proteins of the endoplasmic 
reticulum which conjugate a wide variety of xenobiotics and endogenous compounds 
such as bilirubin and steroid hormones. UGTs catalyze the transfer of 
UDP-glucuronic acid (UDP-GA) to acceptor molecules, which is a process 
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converting lipid soluble compounds into water soluble forms for excretion (Hum et 
aL, 1999; Kuuranne et al., 2003). 
In human, more than 16 UGTs have been characterized and grouped into two main . 
subfamilies, UGT1A and UGT2 (Kuuranne et al., 2003). They are classified 
according to their substrates. Members of UGT1A mainly conjugate xenobiotics 
while that of UGT2 mainly conjugate hormones. Members of the UGT2 family are 
clustered on human chromosome 4ql3 and 4q28 while those of the UGT1A family 
are encoded by a unique locus located at chromosome 2q37. Proteins under the 
UGT1A family are composed of two large domains. The N-terminal domain is 
encoded by a unique first exon while the C-terminal is encoded by four common 
exon 2-5. According to previous studies, the C-terminal, which is identical for all 
UGT1A enzymes, is responsible for UDP-GA binding. On the other hand, the 
structure of the N-terminal determines the substrate specificity of different UGT1A 
proteins (Kuuranne et al., 2003). Currently, it is found that UGT1 locus encodes for 
nine functional enzymes: UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8，1A9 and 1A10. 
UGT2 enzymes are encoded by separate genes, thus they have polypeptide chains 
with different amino acid sequences. Functional enzymes include UGT2A1, 2B4, 
2B7, 2B10, 2B11, 2B15 and 2B17. Most of the UGTs are hepatic enzymes, however, 
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some of them are also expressed in extrahepatic tissues (Tukey & Strassburg, 2000; 
Li et al., 2001; Miners et aL, 2002; Bock, 2003; Kurkela et al., 2003; Kuuranne et al., 
2003). 
1.5.2 UGT1A1 
UGT1A1 belongs to the family UGT1A. According to literatures, its substrates 
include bilirubin, xenobiotics, phenol and estradiol (King et al., 1996; Tukey & 
Strassburg, 2000; Burchell, 2003). Polymorphisms have been identified in the 
UGT1A1 gene promoter, which affect transcriptional activity of the gene. These 
polymorphisms include five, six, seven and eight TA repeats ((TA)5-8TAA) in the 
TATA box. (TA)6TAA allele is the wild type allele. UGT1A1 expression decreases 
as the number of TA repeats increases (Beutler et al., 1998; Guillemette et al, 2000). 
The promoter polymorphism is linked to some inherited diseases; such as Crigler-
Najjar syndromes type I and II, and Gilbert syndrome. Patients suffering from 
Crigler- Najjar syndrome type I completely lack bilirubin glucuronidation while 
those suffering from type II have low amount of conjugated bilirubin in duodenal 
biliary secretions. Both Crigler- Najjar syndromes type I and II are rare genetic traits 
with an absent or low activity of UGT1A1. The patients have mutant alleles in the 
coding region and promoter polymorphism. Gilbert syndrome is a chronic, mild 
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hyperbilirubinaemia with autosomal recessive traits and is caused by promoter 
polymorphism only (Tukey & Strassburg，2000; Miners et al., 2002). 
Several epidemiological studies have been carried out to study the association 
between the promoter polymorphism exists in UGT1A1 and the risk of breast cancer. 
Study has shown that polymorphisms in the TATA box of UGT1A1 which lead to 
low expression level of the gene are associated with increased breast cancer risk 
among Africa Americans (Guillemette et al., 2000). However, another study in 
Caucasian women does not support this association (Guillemette et al, 2001). 
Results of these studies can be affected by many confounding factors like 
environment, diet, etc. 
1.6 Cytochrome P450 I Enzyme Family 
1.6.1 CYP450 Subfamily 
Human Cytochrome P450 (CYP) enzymes belong to a multi-gene super family made 
up of 17 families with constitutive and inducible haem-containing oxidative enzymes. 
They metabolize numerous exogenous and endogenous compounds into reactive 
species. Liver is the main organ for xenobiotic metabolism and contains major CYPs 
(Sy et al., 2001). Variation in CYP expression is determined by one's hormonal 
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status, diet, smoking, age, genotype, and drug exposure (Rodriguez-Antona et al., 
2001). 
Mammalian cytochrome P450 oxidases have about 500 amino acids and a heme 
group at the active site. Cofactors like cytochrome P450 reductase and NADPH, and 
molecular oxygen are required for their function. Cytochrome P450 is named for its 
maximum absorption of light at wavelength 450 nm when the heme iron is reduced 
and complexed to carbon monoxide. They are classified into families and subfamilies 
according to their sequence similarities. Members of the same family share 40% 
amino acid identity while subfamily members share more than 55% amino acid 
identity. 
1.6.2 CYP1A1 
CYP1A1 is one of the most active cytochrome P450 enzymes in converting 
polycyclic aromatic hydrocarbon (PAH) into active species. Formation of DNA 
adducts with these active species is thought to be the initial step in carcinogenesis 
(Morel & Barouki，1998). 
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The human CYP1A1 gene is located at chromosome 15q22-q24 and comprises seven 
exons and six introns. Its mRNA is about 2.8 kb in length (Kawajiri et al., 1986). The 
expression of GYP1A1 is regulated by xenobiotic response element (XRE) and is 
inducible by PAH through the aryl hydrocarbon receptor (AhR) activation pathway 
(Sy et al., 2001; Nebert et al., 2004). 
Epidemiological studies regarding the association between CYP1A1 polymorphism 
and breast cancer risk have shown inconsistent results (Taioli et al., 1995; Taioli et 
al, 1999). Polymorphisms with augmented CYP1A1 activity in African-Americans 
are associated with increased breast cancer risk (Taioli et al., 1999). However,(Singh 
et al., 2006) have shown that CYP1A1 polymorphism alone does not play a 
significant role in the breast cancer risk in Indian women. The dual role of CYP1A1 
in mammary carcinogen activation and estrogen-2-hydroxylation could be 
responsible for inconsistent findings. 
1.6.3 CYP1B1 
Human CYP IB 1 is a newly isolated isoform in the CYP1 family (Sutter et al., 1994). 
CYP1B1 is located at chromosome 2. Its mRNA is about 5.2 kb in length and is 
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composed of three exons. The expression of CYP1B1 protein in normal human tissue 
is low but it is over-expressed in a variety of tumor cells (Murray et al., 2001). 
While CYP1B1 is capable of activating a variety of procarcinogens and promutagens 
including PAH and aryl amines, it is inducible by various polycyclic aromatic 
hydrocarbons (Iwanari et al, 2002). The induction is mediated by the AhR and AhR 
nuclear translocator. Two XREs have been identified to be critical for the induction 
ofCYPlBl (Tsuchiya et al, 2003). 
An epidemiological study has shown that increased CYP1B1 activity in Asian 
women is associated with elevated breast cancer risk (Zheng et al, 2000). However, 
negative findings have also been reported (Lee et al., 2003; Thyagarajan et al., 
2004). 
1.7 Reason why UGT1A1 is being studied 
UGT represents one of the most important classes of phase II drug metabolizing 
enzymes which catalyze the transfer of glucuronic acid to a number of substrate 
molecules in the liver and extrahepatic tissues. Compounds inactivated by glucuronic 
acid conjugation include steroid hormones, such as estrogens and catechol estrogens 
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(Cheng et al., 1998). UGT1A1 is being studied in the current project because it is 
involved in estradiol (E2) and procarcinogen inactivation. And it is expressed in 
mammary glands so it represents a candidate gene in breast cancer (Guillemette et al., 
2000). Besides, epidemiological studies have proven that UGT1A1 expression level 
is associated with breast cancer (Guillemette et al., 2000). Therefore the objectives of 
the current research were investigating the effects of UGT1A1 on the assault of 
xenobiotics and its regulation. 
1.8 Outline of this Study 
1.8.1 Effects of Over-expressing UDP-GIucuronsyltransferase and Cytochrome 
P450 1A1 Against Xenobiotic Assault in Breast Cancer Cells 
UGT1A1 represents a candidate gene for the protection against breast cancer. 
Besides, epidemiological studies have proven that UGT1A1 expression level is 
associated with breast cancer (Guillemette et al, 2000). Therefore in the current 
project, a cell culture model was employed to elucidate the effect of UGT1A1 
against E2 and 7,12-dimethylbenz[a]anthracene (DMBA) attack. 
CYP1A1 is involved in the metabolism of mammary carcinogens, environmental 
estrogens and PAH. Previous studies have demonstrated the association between 
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CYP1A1 genotype polymorphism and breast cancer risk (Taioli et aL, 1999). 
Therefore the effect of CYP1A1 against E2 and DMBA attack were also investigated 
in a cell culture model. 
1.8.2 Effects of Genistein and Resveratrol on Phase I and II Enzymes in a 
Non-cancerous Breast Cell Line 
Phytochemicals are believed to have beneficial effects on health. Previous researches 
have demonstrated that genistein and resveratrol are cancer chemopreventive agents 
(Gallo et al, 2001; Simopoulos, 2004; Levi et al., 2005). As CYP1A1, CYP1B1 and 
UGT1A1 are associated with the risk of breast cancer, we investigated the effects of 
genistein and resveratrol on their expression regulation in the current study 
1.8.3 Effects of UGT1A1 on Cancer Drug Treatment 
UGT1A1 is a phase II drug metabolizing enzyme responsible for glucuronidation of 
drugs and xenobiotics. We therefore investigated if high expression of UGT1A1 
would affect the efficiency of therapeutic drugs. A cell culture model was employed 
to evaluate the effect of UGT1A1 on drugs prescribed for cancer patients. 
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CHAPTER 2, MATERIALS AND METHODS 
2.1 Chemicals 
All restriction enzymes were purchased from New England Biolabs (Ipswich, MA, 
USA). All primers were synthesized by Invitrogen (Grand Island, NY, USA). All 
solvents were HPLC grade and purchased from Merck (Darmstadt, Germany). 
[G-3H]7,12-Dimethylbenz[a]anthracene was obtained from Amersham Pharmacia 
Biotech UK Limited (Buckinghamshire, UK). Estradiol, [2,4，6，7-3H(N)]_ was 
purchased from PerkinElmer，Inc. Other reagents, if not stated, were purchased from 
Sigma (St. Louis, MO, USA). 
2.2 Cell Culture 
MCF-7 cells (ATCC) were grown in RPMI - 1640 phenol red free media 
supplemented with 1% Penicillin-Streptomycin (P/S) and 10% FBS at 37°C, in 5% 
C02 . Phenol red is known to contain an estrogenic contaminant. Transfected cells 
were maintained in RPMI supplemented with 1% P/S, 10% FBS and 500ug/ml 
geneticin at 37°C, in 5% C02 
2.2.1 Maintenance 
When cells reached about 80% confluence, the medium was removed, and the cells 
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were washed with PBS and then trypsinized with trypsin-EDTA for 5 min. The cell 
suspension was transferred to a 15 ml centrifuge tube containing 7 ml PBS and 
pelleted at room temperature for 5 min. The cell pellet was resuspended with fresh 
medium and transferred to new flasks and incubated as described above. For 
experiments, cells were grown in 10% charcoal treated FBS which had been stripped 
of endogenous steroids and RPMI. 
2.2.2. Preparation of Cell Stock 
Semi-confluent cells in 75 cm2 flasks were washed with PBS and trypsinized. After 
centrifugation, the cell pellet was suspended in 500 \x\ RPMI supplemented with 10% 
FBS and transferred into a 2 ml freezing tube containing 500 p.1 FBS and 200 t^l 
DMSO. The tube was put in an isopropanol-filled freezing container (Nalgene, USA) 
and the container was put into a -80°C freezer so that the cell stock was frozen at a 
constant rate of about 1°C /min. Cell stocks were stored at -80°C or liquid nitrogen. 
2.2.3. Cell Recovery from Liquid Nitrogen Stock 
The cell stock was taken out from the liquid nitrogen tank and thawed immediately 
in a 37°C water bath. The cells were plated on a 25cm2 culture flask and incubated at 
37 °c and 5% C02 for 5 hours and then the medium was replaced by fresh medium to 
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avoid death of cells due to toxicity of DMSO. Medium was changed daily for 3 days 
before normal passage of cells. 
2.3 Cloning and Transfection 
Complementary DNA (cDNA) corresponding to UGT1A1 was amplified by reverse 
transcriptase polymerase chain reaction (RT-PCR) using total RNA isolated from 
MCF-7 cells by TRIZOL® (Invitrogen) reagent. The gene fragment was cloned into 
pGEMT-Easy vector (Promega) and was subjected to a second round of PCR with 
restriction sites added. Then the gene fragment with restriction sites was cloned into 
pCDNA 3.1 vector and the recombinant vector was transformed into E.coli (strain: 
DH5a) for amplification. Small scale plasmid purification (Miniprep) was performed 
for plasmid purification. Finally the recombinant plasmid was sent to Macrogen Inc. 
(Korea) for sequencing. Recombinant plasmid with correct sequence was transfected 
into MCF-7 cells with the use of LipofectAMINE PLUS™ reagent. 
2.3.1 Isolation of RNA from Cells and cDNA Synthesis 
Total RNA was extracted from MCF-7 cells by TRIZOL® reagent. 5X105 cells were 
plated to each well of a 6 well plate. Before isolation of RNA, cells were washed 
with PBS for 3 times. One ml TRIZOL® reagent was added to each well and 
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incubated for 5 min at room temperature with gentle shaking. The homogenous 
samples were transferred to a 1.5 ml microtube. Then, 0.2ml chloroform was added 
to each microtubes followed by vigorous shaking and 3 min incubation at room 
temperature. The samples were centrifuged at 12000 g for 15 min at 4�C. Then, the 
upper aqueous layer was transferred to another 1.5 ml microtube to which 0.5 ml 
isopropanol was added. The samples were incubated at room temperature for 10 min 
and centrifuged at 12000 g for 10 min at 4°C- The supernatant was removed and the 
RNA pellet was washed with 1 ml of 75% ethanol with vortexing. Then, the RNA 
was pelleted again and air-dried after discarding the ethanol. Twenty-five DEPC 
water was added to dissolve the RNA which was stored at -80°C. The concentration 
and purity of RNA were determined by OD260/280 ratio. 
Total RNA (5 jig) was denatured at 7 0 � C for 5 min in the presence of 0.025 \ig/[i\ 
oligo-dT (Invitrogen). The samples were cooled on ice. Complementary DNA(cDNA) 
was synthesized using 100 units M-MLV Reverse Transcriptase (USB Corporation) in 
a total volume of 20 according to the manufacture's instructions. Briefly, the 
reactions were conducted in the presence of lxM-MLV reaction buffer and 0.5 mM 
dNTP mixture (Invitrogen) at 37 °C for 60 min and consequently inactivated at 70 °C 
for 10 min. 
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2.3.2 Amplification of UGT1A1 
C D N A corresponding to U G T 1 A 1 was amplified by R T using total R N A isolated 
from MCF-7 cells. Five jig RNA was used for each RT reaction and the final volume 
was adjusted to 20 |il. 
In first round PCR reaction, gene specific primers were used and the sequences are 
shown in table 2.1. The PCR samples, including 5ul cDNA, lul forward primer 
(UGT1A1-F1), lul reverse primer (UGT1A1-R1), 2.5ul 10X PCR buffer, 0.5ul 
10mM dNTPs, 0.2ul high fidelity Taq polymerase and 15ul autoclaved water, were 
heated to 95°C for 5 minutes. Annealing was performed at 57°C for 1 minute and 
extension at 72°C for 2 minutes. 40 PCR cycles were carried out and a final 
elongation step at 72 °C for 5 minutes was included. The PCR products were 
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analyzed on 1.5% agarose gel. 
In the second round PCR reaction, primers with restriction sites Xbal and Hindlll 
added were used and are shown in table 2.1. The PCR samples include 2ul PCR 
product, 0.5ul forward primer (UGT1A1-F2), 0.5 |il reverse primer (UGT1A1-R2), 
2.5 ㈣ 10X PCR buffer, 0.5ul lOmM dNTPs, 0.2 [il high fidelity Taq polymerase and 
20 
19 autoclaved water. The condition was the same as that of first round PCR. 30 
cycles were carried out and the PCR products were analyzed on 1.5% agarose gel. 
Primer Code Sequence 
I ATG GCT GTG GAG TCC CAG GGC GGA CGC CCA 
TCAATGGGTCTT GGA TTT GTG GGC TTT CTT 
UGT1A1-F2— |TAT TCA AGC TTA TGG CTG TGG AGT CCC AG 
" ^ ^ R T |TACGTC TAG ATC AAT GGG TCT TGG ATT T 
^ H J 
Table 2.1 Primer sequence 
2.3.3 Separation and Purification of DNA from Agarose Gel 
One point five % agarose gel was prepared by dissolving agarose in hot TAE buffer 
containing 0.4ug/ml ethidium bromide. DNA samples were loaded into the wells of 
the gel immersed in TAE buffer and separated at 90V for 45 min. 
T h e bands of interest were cut and the DNA purified with the CONCERT™ Rapid 
Gel Extraction Systems. Thirty i^l of Gel Solubility Buffer (LI) was added for every 
10 mg of the gel to completely dissolve it in a 1.5 ml microtube at 50°C with shaking 
occasionally. The mixture was then transferred to a cartridge on a 2 ml wash tube 
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and centrifuged at 12000 g for 1 min. The solution in the collection tube was 
discarded and 0.7 ml Wash Buffer was added to the cartridge which was then 
incubated at room temperature for 3 min and centrifuged again. After discarding the 
buffer in the collection tube, the cartridge-collection tube assembly was centrifuged 
for a further 1 min to remove the residual wash buffer. The DNA was eluted with 
25ul 60°C autoclaved water and collected by centrifugation into a clean microtube. 
The eluted DNA was then stored at -20°C. 
2.3.4 Restriction Digestion 
Restriction digestion was used to prepare DNA inserts for cloning and for the 
confirmation of positive transformants. The DNA inserts (UGT1A1 with restriction 
sites) and the vector (pcDNA3.1) were mixed with restriction enzymes, Xba I and 
Hindlll, and 10X NEB buffer 2 separately. The total volume was brought up to 20ul 
by autoclaved water. The mixture was incubated at 37°C for 2 hours before subjected 
to DNA separation and purification by agarose gel. 
2.3.5 Ligation of DNA Fragment and Vector 
The T4 ligase (400 unit/0) and 10X T4 ligase buffer was used to ligate DNA inserts 
and vector pcDNA3.1 after restriction digestion. The DNA insert and vector were 
22 
mixed at 3:1 concentration ratio with 2 \x\ 10X T4 ligase buffer and 1 T4 ligase. 
The volume was brought up to 20 |il with autoclaved water. The reaction was 
incubated at 14�C overnight. Then the product was then transformed immediately or 
can be stored at -20°C. 
2.3.6 Transformation of DH5a 
The mixture after ligation was transferred into a 1.5 ml microtube containing 200 jj.1 
competent E.coli cells of strain DH5a. The mixture was allowed to stand on ice for 
30 min without any disturbance. The cells were incubated at 42°C for 2 min as the 
heat shock and then chilled on ice for 10 min as the cold shock. Four hundred pi LB 
medium was added into the cell. It is then incubated in a 37°C shaker for 1 hour. The 
mixture was then pelleted. The supernatant was discarded until approximately 200 
medium was left. The pellet was resuspended in the residual medium to spread on a 
LB plate with ampicillin (LBA plate) for selection of transformants. The plate was 
incubated face down at 37°C overnight. Transformants that grew as single colonies 
on the plate were picked and grew in 5 ml LB medium with 0.1% ampicillin (LBA 
medium) at 37°C with shaking overnight. The cultures were screened by PCR with 
appropriate primers and restriction digestion. The products were analyzed by agarose 
gel electrophoresis. Successful transformants were subjected to small scale plasmid 
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isolation (Miniprep). The DNA recombinant was then subjected to gene sequencing. 
. The samples with all-correct sequences were further grown in 150 ml LBA medium 
overnight with shaking. Large scale plasmid isolation was then performed by 
Maxiprep. 
2.3.7 Small Scale Plasmid Purification (Miniprep) 
A single colony of transformed DH5a on a LBA plate was inoculated into 5 ml of 
LBA medium at 37�C with shaking overnight. The overnight culture was transferred 
into a microtube and pelleted, the supernatant was discarded. Plasmids were purified 
by Rapid Plasmid Miniprep. Two hundred and fifty |il of Cell suspension buffer (Gl) 
was added into the microtube, followed by vortexing until homogenous. The 
suspension was then mixed with 100 \i\ of Cell Lysis Solution (G2)，gently mixed by 
inverting the capped tube five times and incubated at room temperature for 5 min to 
lyse the cells. Then, 350 \i\ Neutralization Buffer (M3) was added, mixed 
immediately by inverting the tube five times and centrifuged at 12000 g in a desktop 
centrifuge for 10 min. The supernatant was loaded into a spin cartridge placed in a 2 
ml wash tube and was then centrifuged at 12000 g for 1 min. After disposal of the 
flow-through, the cartridge was placed back into the 2 ml wash tube, 700ul of Wash 
Buffer (G4) containing ethanol was added. The set up was centrifuged at 12000 g for 
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1 min afterwards. After discarding the flow-through, it was centrifuged again at 
12000 g for 1 min to remove residual wash buffer. Lastly, the cartridge was placed 
into a 1.5 ml recovery tube and elution was operated by adding 75 \i\ of TE buffer at 
70°C directly to the center of the spin cartridge, incubating at room temperature for 1 
min and centrifuging at 12000 g for 2 min. 
2.3.8 Large Scale Plasmid Purification (Maxiprep) 
Maxiprep (Marligen Biosciences) was performed to isolate and purify plasmid DNA 
at large scale from DH5a cells. An overnight culture of the transformed DH5a cells 
was pelleted in a 500 ml conical tube by centrifugation at 6000 g for 15 min. The 
supernatant was discarded and the pellet was re-suspended in 6 ml of Cell 
Suspension Buffer (Gl) solution which contained RNase A. Six ml of Cell Lysis 
Solution (G2) solution was added to the re-suspended culture. The mixture was 
mixed by inverting the tube five times and incubated at room temperature for 5 min. 
To neutralize the lysate, 8 ml of Neutralization Buffer (G3) solution was pipetted 
into the lysate, and mixed immediately by inverting the tube five times. Then, the 
mixture was centrifuged at 20000g for 20 min. The supernatant was loaded into a 
spin column on a 50 ml tube and was centrifuged at 3000 g for 5 min by a swinging 
bucket rotor. After discarding the flow-through, the spin column was put back to the 
25 
50 ml tube to be centrifuged again after the addition of 15 ml Wash Buffer (G4) at 
3000 g for 15 min. The lysate was eluted out by adding 4 ml 70°C autoclaved water 
to the spin column and centrifuged at 3000 g for 10 min. 
2.3.9 stable Transfection into MCF-7 Cells with LipofectAMINE PLUS Reagent 
5 x 105 MCF-7 cells were plated in each well of a 6 well plates. The cells were 
allowed to grow until they reached 80% confluent. On the day of transfection, the 
cells were transfected with 1 ^g of the recombinant vector and pcDNA3.1 vector. 
The DNA was pre-complexed and diluted in 100 jjI medium without serum and 
mixed. 6 jil of PLUS reagent was added to the DNA and incubated at room 
temperature for 15 min. 4 |il LipofectAMINE Reagent was diluted in RPMI medium 
without serum in a second tube. The pre-complexed DNA and the diluted 
LipofectAMINE Reagent were combined and incubated for 15 min at room 
temperature. While the complex was forming, medium on the cells was replaced with 
0.8ml transfection medium. The DNA-PLUS LipofectAMINE Reagent complexes 
were added to each well containing fresh medium. The mixture was mixed gently 
and then incubated at 37°C at 5% C02 for 3 hours. After that, the volume of medium 
was increased to normal volume with serum containing medium so as to bring the 
final concentration to that of normal growth medium. After incubation for 24 hours， 
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the medium on cells was replaced by the fresh culture medium. After a further 48 
hours, stably transfected cells were selected by 500 jag/ml geneticin (G418). 
Selective medium was replaced every 3 days and the transfected cells were selected 
for 21 days. 
2.4 Analytical Procedures 
2.4.1 Western Blot Analysis 
The cells were cultured in a 6-well plate and allowed to attach for 24 hours followed 
by drug treatment. To harvest the cells, they were washed twice with OBS and 
scraped from wells with lysis buffer (25mM Tris-HCl pH 8.8，50mM NaCl, 0.5% 
NP40，0.5% Deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (Roche 
Applied Bioscience, Indianapolis, IN, U.S.A.), and 1 mM sodium orthovanadate 
were added. They were sonicated for 15 s, and then centrifuged at 10000 g for 10 
min at 4°C. The lysates were transferred to a new tube and stored at -80°C until use. 
For immunoblot detection, an equivalent amount of each lysate protein was resolved 
through 12.5% SDS-polyacrylamide gel electrophoresis and electrophoretically 
transferred to a nitrocellulose membrane, followed by blocking with 5% skimmed 
milk. UGT1A, estrogen receptor (ER), Bcl-2, Bax and p-actin were detected by 
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immunoblotting. Membranes were then incubated with mouse or rabbit IgG 
horseradish peroxidase conjugate (Dako) for 1 hour at room temperature. 
Immunoconjugates were visualized by chemiluminescence using ECL (Amersham). 
2.4.2 Measurement of Cell Proliferation (MTT assay) 
Cell viability was assessed by 3-(4,5 d imethyl th iazol -2-yl ) -2 ,5-diphenyl tetrazolium 
b r o m i d e (MTT) staining described by Mosm讓（1983). Cells were plated in 96-well 
plates at 8,000 cells per well and allowed to attach for 24 hours. After drug treatment, 
50 Hi of 1 mg/ml MTT was added and the cells were incubated at 37°C for 3 hours. 
Then lOOul of DMSO was added and the plate was allowed to stand at room 
temperature for 30 min. Cell viability was determined by the absorbance at 600nm. 
2.4.3 Measurement of DMBA-DNA Adduct Formation 
The assay was performed as previously described (Chan et al 2002) and was 
performed in a 6-well plate. 5X105 cells were placed in each well and allowed to 
attach for 24 hours. Then they were treated with 0.1 昭/ml of3H-DMBA. After 16 
h o u r s , cells were washed with cold PBS, trypsinized and pelleted. Cells were 
incubated on ice in nuclei separating buffer (10 mM Tris-HCl, PH7.5，320 mM 
sucrose, 5mM magnesium chloride and 1% Triton X-100) to separate the nuclei 
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which were then separated from cell debris by centrifugation at 4000 g for 10 min at 
4°C. The nuclei were lysed by 400 jil nuclei lysis buffer (1% SDS in 0.5 M Tris. 20 
jllM EDTA and 10 mM NaCl, pH9) and then treated with 20 |il 20 mg/ml Proteinase 
K for 2 hours at 48�C. After that the samples were cooled at room temperature and 
residual proteins were salted out by the addition of 150 \i\ saturated NaCl. The 
samples were then subjected to centrifugation at 10000 g for 30 min at 4°C. Genomic 
DNA was isolated from supernatant by ethanol precipitation and redissolved in 
autoclaved distilled water. DNA samples having an OD260nm/280nm ratio larger 
than 1.9 are used for scintillation counting. Samples were mixed with 4 ml cocktail 
in a vial and were subjected to scintillation counting. 
2.4.4 Comet Assay 
Cells were placed in a 6-well plate and allowed to attach for 24 hours. After 
treatment of drugs, cells were washed with PBS, trypsinized and pelleted. The cell 
pellet was resuspended in PBS. Cells at 2X105 cells/ml were combined with molten 
low melting (LM) agarose at 42°C at 1:10. 75 jil of the above mixture was pipetted 
and spread onto CometSlide™. The slide was placed at 4°C in dark for 30 min for 
better adherence and then immersed in prechilled lysis solution and kept at 4°C in 
dark for 60 min. The slides were left in alkaline solution for 60 min for room 
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temperature in dark prior to electrophoresis. Alkaline electrophoresis was performed 
a t 4�C in dark. Alkaline solution was poured just covered the samples. The 
electrophoresis was performed for 30 min at 25V. The slides were rinsed with ddH20 
after electrophoresis and immersed in 70% ethanol for 5 min. The slides were dried 
in air and then stained with 50 …SYBR Green. After staining, DNA samples are 
viewed by using a nikon TE2000 microscope with relevant filters. 
2.4.5 Relative Quantitative Real Time PCR 
2.4.5.1 Real Time PCR Using TaqMan Probe 
Target mRNA levels were determined by relative quantitative real-time PCR using the 
OpticonTM 2 System (MJ research, Waltham, MA, USA). The reaction mixture 
consisted of 10 � TaqMan Universal PCR Master Mix (Applied Biosystems), 0.5 … 
UGT1A1 (FAM label), CYP1A1 (FAM label), CYB1B1 (FAM label) or house 
keeping gene GAPDH (FAM label) TaqMan probe (Applied Biosystems) and 10 … 
cDNA in a final volume of 20 卟 Amplifying conditions were 5 0 � C for 2 min and 95 
� C for 10 min, followed by 45 cycles at 9 5 � C for 15 sec and 6 0 � C for 1 min. The 
experiment was carried out in triplicate, and target and reference genes were amplified 
in separate wells. 
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2.4.5.2 Statistical Analysis of2"AACT Comparative Gene Expression 
The method of 2"AACT was applied to determine comparative gene expression of 
samples relative to control (Livak & Schmittgen, 2001). The mean fold change in 
expression of target gene compared with control was calculated with the equation: 
Relative target gene expression = 2" , where AACT = (CT target — C T h ouse keeping)sample “ 
(CTtarget 一 C T h o u s e keeping)control-
2.4.6 Flow Cytometry 
Cells were cultured in a 6-well plate. After drug treatment, the cells were trypsinized, 
washed and suspended in Falcon culture tubes. The cells were fixed with 1 ml of 
70% EtOH and stored at 4°C overnight. After fixing with 70% EtOH, the cells were 
washed twice and resuspended in staining solution (40 mg/ml propidium iodide and 
8 mg/ml RNase A in PBS with 0.1%Triton X-100 and 0.1 mM EDTA). After 30 min 
incubation at room temperature, the percent of subdiploid cells were determined by 
FACSORT flow cytometer. 
2.4.7 EROD Activity in intact cells 
The assay method was performed as previously described (Ciolino & Yeh, 1999a). In 
brief, MCF-7 cells in 96-well plates were treated with 2.5 jxM DMBA and various 
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concentrations of phytochemicals. The medium was then removed and the cells were 
washed twice by 100 PBS. Ethoxyresorufm-O-deethylase (EROD) activities, 
which are indicatives o fCYPlAl enzyme activities, were then carried out. 100 …of 
5 i^M ethoxyresorufin (ER) in PBS with 1.5 mM salicyclamide was added to each 
w e l l , and incubated at 37�C for 15 min. The reaction was stopped by 100 of 
ice-cold methanol, and the resorufin generated was measured by a FLUOstar Galaxy 
microplate reader (BMG Labtechnologies) with an excitation of 544 nm and 
emission at 590 nm. 
2.4.8 High Performance Liquid Chromatography 
Cells were seeded in 100 mm dish and allowed to attach for 24 hours. The cells were 
treated with 3H estradiol for 24 hours. After drug treatment, the cells medium was 
extracted by ethyl acetate for 3 times, dried by nitrogen gas and redissolved in 200 … 
methanol. After centrifugation, 70 …of the supernatant was injected in to the HPLC 
system (Shimadzu, Tokyo, Japan). A 250 讓 x 4.6 画 i.d” 5 n C18 reversed phase 
column (Alltech, Deerfield, IL, USA) was used for the separation of estradiol and 
estradiol-3-glucuronide. Estradiol and estradiol-3-glucuronide were determined by 
using an UV detector (Shimadzu) at 280 nm, as well as a radioactivity detector 
(Raytest, Straubenhardt, Germany). 
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The mobile phase consisted of 10% methanol (solvent A), 100% methanol (solvent B)， 
and 1 mM perchloric acid in 30% acetonitrile (solvent C). The solvent gradient 
(solvent A/solvent B/solvent C) used for eluting estradiol and estradiol-3-glucuronide 
was: an initial composition of 75:10:15，50 min to 0:85:15, 90 min to 75:10:15. 
Fig.2.1 illustrates the standard retention time of estradiol and estradiol-3-glucuronide 
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Fig.2.1 A chromatogram showing retention time of estradiol and 
estradiol-3 -glucuronide standard 
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2.5 Statistical Analysis 
A Prism® 3.0 (GraphPad Software, Inc., CA, USA) software package was utilized 
for statistical analysis. Results were expressed as means 士SD of the indicated number 
of independent experiments. One-way ANOVA followed by Bonferroni's Multiple 
Comparison Test if significant differences (p < 0.05) were observed. 
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CHAPTERS, EFFECTS OF OVER-EXPRESSING 
UDP-GLUCURONOSYLTRANSFERASE AND CYTOCHROME 
P450 1A1 AGAINST XENOBIOTIC ASSAULT IN BREAST 
3.1 Introduction 
UGT1A1 represents a candidate gene for the protection against breast cancer. 
Epidemiological studies have demonstrated that high UGT1A1 expression level is 
associated with increased risk of breast cancer (Guillemette et al., 2000). In the 
current research, stably transfected M C F - 7 cells (MCF-7UGTIAI) were employed to 
elucidate the protective effect of UGT1A1 against estrogen and DMBA attack. 
3,17p-Dihydroxy-1,3,5(10)-estratriene or estradiol (E2) is a major form of 
endogenous estrogen and its structure is shown in Fig. 3.1. Previous studies have 
shown that the development of breast cancer is closely related to the responsiveness 
of mammary tissues to estrogenic substances (Miller & O'Neill，1990). All breast 
cancers depend on estrogen for growth during early stage of development. E2 
regulates the growth of some breast tumors via induction or suppression of key 
growth regulatory factors (Lippman et al., 1986; Yashwanth et al., 2006). 
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II 广 O H 
" 3 � v 
1| J H 1 H 
i l \ J Fig. 3.1 Structure of estradiol 
DMBA is a polycyclic aromatic hydrocarbon (PAH) that is commonly used to induce 
breast cancer in animal models. PAHs are one class of the environmental carcinogens 
which can cause cellular transformations by producing highly reactive carcinogenic 
electrophiles after metabolic activation by some drug-metabolizing enzymes. The 
electrophiles generated interact with DNA and form DNA-adducts. Fig. 3.2 shows 
the structure of DMBA. 
CH 3 R ^ N 
I I 
C H 3 Fig. 3.2 Structure of DMBA 
UGT is a phase II enzyme and can perform detoxifying function. It removes 
environmental carcinogens and avoids the generation of DNA-damaging reactive 
species from these compounds. In addition, it facilitates the conjugation of estrogen, 
36 
thus cell proliferation and estrogen-related responses can be suppressed. My 
hypothesis was that UGT1A1 alone can be protective in the early stage of breast 
carcinogenesis, i.e. DNA damage from PAH-attack and cell proliferation from 
estrogen. 
• CYP1A1 metabolizes some procarinogens, such as PAH into ultimate carcinogens. It 
is also responsible for hydroxylation of estrogen, resulting in the formation of 
catechol estrogens, which can be tumor initiators (Cavalieri et al., 1997; Zhu & 
Conney, 1998; Yager, 2000). MCF-7 cells transfected with CYP1A1 (MCF-7CYPIAI) 
were established in our laboratory before. In the current study, this cell line was 
employed to evaluate the effect of CYP1A1 on xenobiotic assault. 
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3.2 Results 
3.2.1 Effectiveness of Transfection 
To investigate the protective effect of UGT1A1 against breast cancer development, 
UGT1A1 was stably transfected into MCF-7 cells. The effectiveness of transfection 
was determined by RT-PCR and Western blot. The result of RT-PCR as presented in 
Fig. 3.3 indicated the amplified fragment was about 1600 bp, conforming to human 
UGT1A1. The band intensity of Lane 2, 3 (clone 1) and 14, 15 (clone 7) were higher 
than that of other samples. These two clones were subjected to Western blot 
screening. The result of Western blot was shown in Fig. 3.4. A 59 kDa 
immunoresponsive band, which corresponded to UGT1A1 was observed. Both clone 
1 and 7 had higher expression level of UGT1A1 than control cells and clone 7 had 
higher expression level of UGT1A1 than clone 1. Clone 7 was chosen and subjected 
to further analysis. 
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Lane Sample 
1, 24 250bp Marker 
2, 3 Clone 1 
4’ 5 Clone 2 
6，7 Clone 3 
8’ 9 Clone 4 
10,11 Clone 5 
12, 13 Clone 6 
14, 15 Clone 7 
16, 17 Clone 8 
18,19 Clone 9 
20，21 Clone 10 
22, 23 Clone 11 
Fig. 3.3 RT-PCR screening for high expression clone. The band intensity of clone 1 
and clone 7 were highest, therefore these two clones were subjected to 
Western blot screening. 
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Control Clone 7 Clone 1 
UGT1A1 59kDa 
P-actin 42kDa 
Fig. 3.4 Western blot screening for high expression clone. Clone 7 showed the 
highest level of UGT1A1 protein expression 
40 
3.2.2 Cell Proliferation Experiments 
To investigate whether the elevated UGT1A1 level inhibited estrogen-induced cell 
growth, transfected MCF-7 cells were treated with E2 and grown in charcoal-treated 
FBS and RPMI medium. In 0.1 nM E2 treatment, cell number of vector-transfected 
cells (MCF-7COntroi) had increased 338%, non-transfected MCF-7 cell growth had 
increased 331% while transfected cells (MCF-7UGTIAI) growth had increased 237% 
(Fig. 3.5). In samples treated with 1 nM E2, the growth of MCF-7contro丨 and 
non-transfected MCF-7 cells had increased by around 3.5 fold while the growth of 
MCF-7UGTIAI cells had increased by 2 fold. In 10 nM E2 treatment, the growth of 
MCF-7controi cells and non-transfected cells had increased by 4 fold while the growth 
of MCF-7UGTIAI cells had increased by about 2.5 fold. Upon E2 administration, the 
proliferation of MCF-7C0ntr0| or non-transfected MCF-7 cells was significantly higher 
than that of MCF-7UGTIAI cells. The differential cell proliferations might be caused 
by the difference in E2 metabolism. 
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Effect of Over-Expressing UGT1A1 on Cell Proliferation under Estradiol 
Treatment # 
4 5 0 _ ff � * ~ ^ 
450 r ~ r = \ ！—\ 
400 * ^ 
I 3 0 0 ,—膠-~7•- DMCF"7UGTIAI 丨 IBifc 
* 0 0.1 1 10 
[Estradiol]/nM 
Fig. 3.5 Effect of over-expressing UGT1A1 on cell proliferation upon E2 treatment. 
Transfected cells showed a significant reduction in cell proliferation upon 
E2 treatment. Values are means ±SD, n=3. Means marked (*) are 
significantly lower than MCF-7 cells (p < 0.001). Means marked (#) are 
significantly lower than MCF-7controi cells (p<0.001). 
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3.2.3 Regulation of Estrogen Receptor (ER) Expression 
E2 treatment initates the complex regulation of hormone receptors and growth factors 
and results in cell growth. Fig. 3.6 showed the result of the immunoblot analysis of 
E R in MCF-7UGTIAI cells upon E 2 treatment. The cells were grown in R P M I medium 
supplemented with charcoal-treated FBS and treated with E2 for 48 hours. 
MCF-7COntroi and non-transfected MCF-7 cells exhibited a dose-dependent decrease in 
ER upon E2 treatment. In contrast, the extent of reduction in ER expression level in 
MCF-7UGTIAI cells was not as much as that observed in MCF-7controi and 
non-transfected MCF-7 cells. The Western blot of p-actin was shown in Fig. 3.6, 
which indicated each lane contained the same amount of protein. 
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Estrogen Receptor 
E2： OnM O.lnM InM lOnM 
MCF-7U G T IAI 54.6kDa • 丨 矿 -
MCF-7controI 54.6kDa W ^ ^ f m m ^ 
MCF-7 54.6kDa . � � 
p-actin 
E2： OnM O.lnM InM 
MCF-7UGTIAI 42kDa mm — ^ ^ 卯 H II 丨麵_ 
MCF-7controi 42kDa 丨丨_ i.> ,,1,, 
MCF-7 42kDa wm^mmmmm i mmmmmmmmm 
Fig. 3.6 Irnmunoblot analysis of the effect of E2 on ER expression in 
MCF-7UGTIAI, MCF-7CONTROI and M C F - 7 non-transfected cells. Cells 
were treated with various concentration of E2. Sample cell lysates 
were obtained after 48 h. 
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3.2.4 Formation of DMBA-DNA adduct formation 
The metabolism of DMBA might be affected because of the elevated level of 
UGT1A1. Fig. 3.7 showed that the covalent binding of DMBA-DNA was reduced by 
30% in UGT1A1 transfected cells. 
Effect of Over-Expressing UGT1A1 on DMBA-DNA 
Adduct Formation 
120 
I 100 m m m m ^ m ： i 
^^M 
< c 80 ^ 
1 § 6 0 一 
20 
q B ^ H H H I I 1 
MCF-7controi MCF-7UGT1A1 
Cell Type * P < 0 . 0 5 
Fig. 3 .7 Relative D M B A - D N A adduct formation in M C F - 7 c o n t r o i and MCF-7UGTIAI 
cells. Cells were treated with 0.1 |ig/ml tritiated DMBA for 1 day. DNA 
was isolated and counted in a scintillation counter. Values are means 士SD, 
n二3. Means marked (*) are significantly lower than MCF-7c�ntr�i cells (p < 
0.05). 
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3.2.5 Single Cell Gel Electrophoresis (Comet Assay) of DMBA-induced DNA 
Damage in MCF-7UGTIAI cells 
Comet assay is able to detect single strand DNA damage in cells with high sensitivity. 
Therefore we performed this assay to determine the DNA damage induced by 
D M B A in MCF-7C Ontroi cells and MCF-7UGTIAI cells. Fig. 3 .8 showed the microscopic 
images of comet assay. Cells with fragmentated DNA tails were regarded as damage 
cells while those without tails were regarded as intact cells. As shown in Fig. 3.9, 
both MCF-7controi cells and MCF-7UGTIAI cells had damaged cells when treated with 1 
|iM and 5 JIM DMBA; however, the percentage of intact cells of MCF-7UGTIAI was 
significantly higher than that of MCF-7controi cells (p<0.05). This indicated that 
over-expression of UGT1A1 offered protection towards PAH toxicity. 
46 
Fig. 3.8 Effect of over-expression of UGT1A1 on DMBA-induced DNA damage in 
MCF-7 cells. Cells were seeded in 6-well culture plates and treated with 
DMBA. After a 72 h treatment, cells were disaggregated with 
trypsin/EDTA prior to comet assay as described in Materials and Methods. 
The microscopic slides were visualized with epifluorescence using a nikon 
TE2000 microscope. 
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Percentage of Intact Cells DMBA-treated Cells 
100 -1 —^—•——— 
- F ^ i i ^ ^ — — 一 
I 50 — • • r ^ r r -
s o — I • # _ 口 D 
口 MCF-7control 2 0 _ ^ H ^ H I l t ^ H • MCF-7UGT1A1 
0 -I ^ _ _ I I #p<0.05 
0 1 5 * p<0.05 
[DMBA]/ pM + P<0.05 
Fig. 3.9 Comet-forming activity of D M B A in MCF-7 c o n t ro i and MCF-7UGTIAI cells. 
Cells were seeded in 6-well culture plates and treated with DMBA. After a 
72 h treatment, cells were disaggregated with trypsin/EDTA prior to comet 
assay as described in Materials and Methods. Cells with fragmentated 
DNA tails were regarded as damaged cells while those which did not 
possess tails were regarded as intact cells. Values are means 士 SD, n = 3. 
Means marked (#) and (+) are significantly lower than vehicle 
(DMSO)-treated cells (p < 0 .05) . Means of MCF-7UGTIAI cells marked with 
(*) are significantly higher than MCF-7C0ntr0| cells treated with same 
concentration of DMBA (p<0.05). 
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3.2.6 HPLC for Estradiol-glucuronidation Analysis 
Cells were treated with InM 3H E2. After a 24-hour incubation at 37°C, the medium 
was extracted by ethyl acetate for 3 times, dried by nitrogen gas, redissolved in 
methanol and subjected to HPLC/scintillation detector as described in Materials and 
Methods. The ratio of estradiol to estradiol-3-glucuronide was 1:0.5 and 1:0.19 in 
MCF-7UGTIAI and MCF-7contr�i cells respectively. 
Ratio of estradiol: estradiol-3-glucuronide 
MCF-7UGTIAI 
MCF-7control 1:0.19 
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Fig. 3.10 A chromatogram showing separation of estradiol and 
estradiol-3-glucuronide in MCF-7 c o n tro i ( A ) and MCF-7UGTIAI (B) cells 
using a radioactive detector 
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3.2.7 Single Cell Gel Electrophoresis (Comet Assay) of DMBA or E2-induced 
D N A Damage in MCF-7CYPIAI cells 
Comet assay was performed to determine the DNA damage induced by DMBA or E2 
in MCF-7COntroi cells and MCF-7CYPIAI cells. Images of comet assay were taken and 
damaged cells were enumerated (Fig. 3.11 and 3.13). Cells with fragmentated DNA 
tails were regarded as damage cells while those without tails were regarded as intact 
cells. As shown in Fig. 3.12, the percentage of intact cells in both 1 |iM or 5 |iM 
DMBA-treated MCF-7controi cells and MCF-7CYPIAI cells was significantly lower than 
vehicle (DMSO)-treated cells (p<0.05). The percentage of intact cells of 
MCF-7CYPIAI was significantly lower than that of MCF-7controi cells (p<0.05). This 
indicated that over-expression of CYP1A1 increased PAH toxicity. 
The comet forming activities of E2 in MCF-?CYPIAI and MCF-7controi cells were 
analyzed as shown in Fig. 3.14. E2 induced DNA damage in cells in a 
dose-dependent manner in both MCF-7CYPIAI and MCF-7COntroi cells. In 10 nM E2 
treatment, the percentage of intact cells of MCF-7CYPIAI was significantly lower than 
that of MCF-7COntroi cells. In 100 nM E2 treatment, the DNA damages in both types of 
cells were similar. 
51 
Fig. 3.11 Effect of over-expression of CYP1A1 on DMBA-induced DNA damage in 
MCF-7 cells. Cells were seeded in 6-well culture plates and treated with 
DMBA. After a 72 h treatment, cells were disaggregated with 
trypsin/EDTA prior to comet assay as described in Materials and Methods. 
The microscopic slides were visualized with epifluorescence using a nikon 
TE2000 microscope. 
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Fig. 3.12 Comet-forming activity of D M B A in MCF-7control and MCF-7CYPIAI cells. 
Cells were seeded in 6-well culture plates and treated with DMBA. After a 
72 h treatment, cells were disaggregated with trypsin/EDTA prior to comet 
assay as described in Materials and Methods. Cells with fragmentated 
DNA tails were regarded as damaged cells while those which did not 
possess tails were regarded as intact cells. Values are means 士 SD, n 二 3. 
Means marked (*) and (+) are significantly lower than vehicle 
(DMSO)-treated cells (p < 0.05). Means of MCF-7CYPIAI cells marked with 
(#) are significantly lower than MCF-7COntroi cells treated with same 
concentration of DMBA (p<0.05). 
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Fig. 3.13 Effect of over-expression of CYP1A1 on E2-induced DNA damage in 
MCF-7 cells. MCF-7CYPIAI (A) or MCF-7controi (B) cells were seeded in 
6-well culture plates and treated with DMBA. After a 24 h treatment, cells 
were disaggregated with trypsin/EDTA prior to comet assay as described 
in Materials and Methods. The microscopic slides were visualized with 
epifluorescence using a nikon TE2000 microscope. 
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Fig. 3.14 Comet-forming activity of E2 in MCF-7controi and MCF-7CYPIAI cells. Cells 
were seeded in 6-well culture plates and treated with E2. After a 24 h 
treatment, cells were disaggregated with trypsin/EDTA prior to comet 
assay as described in Materials and Methods. Cells with fragmentated 
DNA tails were regarded as damaged cells while those which did not 
possess tails were regarded as intact cells. Values are means 士 SD，n = 3. 
Means marked (*) and (+) are significantly lower than vehicle 
(ethanol)-treated cells (p < 0.05). Means of MCF-7CYPIAI cells marked with 
(#) are significantly lower than MCF-7c�ntr0i cells treated with same 
concentration of E2 (p<0.05). 
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3.3 Discussion 
Over-exposure to estrogen and carcinogen can increase the risk of breast cancer. 
Most chemical carcinogens generate reactive electrophilic intermediates which 
interact with DNA and generate lesion on it. Mutations arised from defective or 
deficient repair system may subject the cells to preneoplastic changes. Estrogens are 
related to breast carcinogenesis because it is required for the clonal expansion of 
mutated cells and the subsequent development of breast cancer (Henderson et al., 
1982; Kelsey & Whittemore，1994; Travis & Key, 2003). 
UGT1A1 is a major contributor to E2-glucuronide formation. Individuals deficient in 
UGT1A1 present a 70% decrease in the glucuronidation of E2 compared to their 
normal counterparts (Guillemette et al., 2000). A low level UGT1A1 may result in a 
high level of circulating estrogen, which increases breast cancer risk. Furthermore, a 
recent study has found that E2 down-regulated the expression of UGT1A1 in a 
MCF-7 derived cell line (Vendrell et al., 2004). This may further increase the 
intracellular estrogen level in low UGT1A1 transcription variants. 
In this study, the estrogen-responsive breast cancer cell line MCF-7 was used to 
evaluate the effect of over-expressing UGT1A1 on xenobiotic assault. Estradiol (E2) 
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is a major endogenous estrogen, thus E2 is an index estrogen. Since estrogen plays an 
important role in the regulation of cell proliferation of some ER+ breast tumors via 
inducing or suppressing key growth factors, elevated level of UGT1A1 in MCF-7 
cells should alter the cellular pool of estrogen. The result could be changes in cell 
proliferation and ER expression. Results of the current study demonstrated that an 
elevated level of UGT1A1 in MCF-7 cells was associated with decreased cell 
proliferation. This could be explained by the fact that UGT1A1 conjugated E2 to 
glucuronic acid and thereby inactivated E2. In non-transfected cells and MCF-7controi 
cells, the expression of UGT1A1 was too low and unable to render E2 inactive. 
Estrogens are important in regulating proliferation of some breast tumors via the 
induction or suppression of key growth regulatory factors. E2 is documented to be 
autoregulatory, down-regulating the expression of ER in MCF-7 cells (Molis et al., 
1995). The present research showed consistent findings with this study. In 
non-transfected MCF-7 cells and MCF-7controi cells, there was a dose-dependent 
reduction in ER expression with E2 treatment. In contrast, the reduction in ER 
expression upon E2 treatment was not as significant as that in non-transfected cells 
and MCF-7COntroi cells. These observations agreed to our hypothesis. 
Estradiol-3-glucuronide is the major glucuronidation product of estradiol catalyzed 
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by UGT1A1 (Senafi et al., 1994). HPLC analysis showed that the 
estradiol:estradiol-3-glucuronide ratio was 1:0.5 and 1:0.19 in MCF-7UGTIAI and 
MCF-7controi cells respectively (Table 3.1). The activity of glucuronidation was 
higher in MCF-7UGTIAI cells. This explained the above observation in the current 
study. 
In both cell proliferation experiment and ER expression analysis, the results 
supported our hypothesis that UGT1A1 conjugated E2 and rendered it inactive. 
HPLC analysis further confirmed our hypothesis. The formation of 
estradiol-3-glucuronide was higher in MCF-7UGTIAI cells than MCF-7COntroi cells. 
Therefore, the effects of estradiol on the stably transfected cells was minimized. This 
observation is consistent with previous findings, which low transcription variants of 
UGT1A1 were associated with increased breast cancer risk (Guillemette et al, 2000). 
In addition, the current study demonstrated that elevated level of UGT1A1 in MCF-7 
cells could reduce DMBA-DNA adduct formation. Comet assay also showed that 
over-expression of UGT1A1 reduced the DNA damage caused by DMBA. Elevated 
level of UGT1A1 in MCF-7 might also reduce the cytotoxicity by conjugating the 
reactive electrophilic species or epoxide of DMBA to glucuronic acid. Our findings 
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were consistent with previous studies. According to Yueh et al (2001), early down 
regulation of the UGTs in premalignant and malignant tumor tissues may be a 
prerequisite of cellular carcinogenesis. Besides, our laboratory found that chalcones 
as well as lycopene, which could induce UGT enzymes, had protective effect against 
DMBA-induced DNA damage (Wang, unpublished). All these results showed that an 
elevated level of UGT1A1 could be beneficial in reducing breast cancer risk through 
its action in detoxifying procarcinogens. 
On the other hand, over-expression of CYP1A1 resulted in a higher level of DNA 
damage caused by DMBA and E2 in MCF-7 cells, as shown in Comet assay. Our 
laboratory had previously demonstrated that the DMBA toxicity was lowered when 
CYP1A1 expression or activity was suppressed (Chan et al., 2002; Chan & Leung, 
2003; Wang et al., 2005). Ciolino et al (2002) have also showed that a reduction in 
CYP1A1 activity alleviates DMBA-induced apoptosis. Besides, CYP1A1 catalyzes 
the 2-hydroxylation of estrogen (Zhu & Conney，1998; Yager, 2000). Although 
2-hydroxyestradiol is not as carcinogenic as the CYP1B1 metabolized product, 
4-hydroxyestradiol, it might also undergo redox cycling to generate free radicals and 
the reactive semiquinone/quinone intermediates (Henderson et al., 1991; Li et al, 
1995). It was possible that CYP1A1 generated oxidative damage in the cells and 
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caused single strand break during the redox cycling process. Therefore suppression 
of CYP1A1 could be a protective mechanism against breast cancer. 
In summary, results of this study implicated that an elevated level of UGT1A1 and 
suppression on CYP1A1 might be protective towards xenobiotic-induced DNA 
damage. Dietary compounds that can modulate the expression of these two enzymes 
might help preventing breast cancer. In future, other experiments have to be carried 
out to further confirm the protective effect of UGT1A1. The effect of UGT1A1 
activity should also affect the regulation of hormone receptors and growth factors. In 
addition to ER, the expression of progesterone receptor (PR) and the potent growth 
factor TGF-pl in the transfected cells should be determined by Western blot. The 
effect of UGT1A1 on the genotoxicity of DMBA was detected by measuring the 
formation of DMBA-DNA adduct and comet assay in the current study. Further 
confirmation by doing cell survival experiment is suggested. 
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CHAPTER 4 EFFECTS OF GENISTEIN AND RESVERATROL 
ON PHASE I AND II ENZYMES IN A NON-CANCEROUS 
BREAST CELL LINE 
4.1 Introduction 
The incidence of breast cancer is lower in Asian countries when compared with 
Western countries; however, no difference in breast cancer incidence is found 
between Asian descendents and other women in America (Ziegler et al., 1993). 
These results suggest that environment may play a role in the etiology of breast 
cancer. The beneficial effects of phytochemicals towards cancer have been proven by 
epidemiologic studies. A lower incidence rate of human cancers is associated with 
increased consumption of vegetables, fruits and beans (Kuo, 1997). 
Phytochemicals are compounds found in plants. They are not required for normal 
functioning of our body but may have a beneficial effect on health or active role in the 
amelioration of disease. Phytoestrogens, monoterpenes and carotenoids are commonly 
studied phytochemicals. 
Genistein is one of the major isoflavones isolated from soy. Its structure is shown in 
Fig. 4.1. Previous studies have elicited conflicting results on the cancer-protective 
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roles of genistein. Pubertal administration of genistein could reduce breast cancer 
incidence in rats (Hilakivi-Clarke et al, 1999; Lamartiniere et aL, 2002), while soy 
given after weaning has been proven to be ineffective on carcinogenesis induced by 
DMBA (Appelt & Reicks, 1999). Gallo et al (2001) have shown that genistein 
reduces the percentage of poorly differentiated tumors. In a recent study, genistein 
has been proven to be effective in delaying the latency of mammary tumor 
development in a spontaneous carcinogenesis model (Jin & MacDonald, 2002). In 
contrast, genistein has been demonstrated to increase DMBA-induced mammary 
tumors in ERa-intact mice and encourages the proliferation of MCF-7 tumors in 
athymic mice (Ju et al., 2001) and Sprague-Dawley rats (Allred et al., 2004). A 
recent report has demonstrated that administration of genistein or daidzein alone does 
not result in significant mutagenic or carcinogenic changes in mammary tissues in 
ovariectomized or ovary-intact rats; however administering genistein and daidzein in 
a mixture has reduced DMBA-induced mutagenicity and carcinogenicity in 
mammary tissues significantly (Manjanatha et al., 2006). These reports have shown 
inconsistent results regarding the chemopreventive effect of genistein, but the 
confounding results could be due to the phytochemical's differential actions on the 
initiation, promotion and progression stages. 
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Resveratrol (5-[(E)-2-(4-hydroxyphenyl)-ethenyl]benzene-l,3-diol) is a non-flavonoid 
phytoestrogen found in certain red grapes, peanuts, blueberries, some pines, and the 
roots and stalks of Japanese knotweed and giant knotweed. Resveratrol is widely 
studied as a cancer chemopreventive agent. Previous epidemiological studies have 
shown that resveratrol intake is inversely associated with breast cancer risk 
(Simopoulos, 2004; Levi et al., 2005). Resveratrol has antioxidant, anti-estrogenic 
and anti-inflammatory properties, and may induce apoptosis as well as modulate cell 
cycle arrest in breast cancer cell lines (Le Corre et al., 2005). Resveratrol has also 
been shown to inhibit cytochrome P450 (CYP) 1A1 (Ciolino & Yeh, 2001) and 
cyclooxygenase (COX) enzymes (Seaver & Smith, 2004; de la Lastra & Villegas, 
2005). The structure of resveratrol is shown in Fig. 4.1. 
OH O R ^ V ^ 
H0XX0j 
H O ^ ^ O Genistein 
T T 
O H Resveratrol 
Fig. 4.1 Structure of genistein and resveratrol 
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Epidemiological studies have suggested an inverse correlation between consumption 
of fruits and vegetables and certain cancer incidence rates (Steinmetz & Potter，1996; 
Kuo, 1997). Therefore, phyotchemicals are believed to have positive impact on 
health. Both genistein and resveratrol are widely studied for their chemopreventive 
effects. 
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor which can 
be activated by polycyclic aromatic hydrocarbon (PAH). Upon ligand binding, the 
cytosolic AHR translocates to the nucleus and dimerizes with aryl hydrocarbon 
receptor nuclear translocator (ARNT). The heterodimer binds to specific enhancer 
sequences called xenobiotic response elements (XRE) which are located at the 
promoter region of a number of genes, including CYP1A1, CYP1B1 (phase I 
enzyme) and UGT1A1 (phase II enzyme). CYP1A1 and CYP1B1 are capable of 
activating a variety of procarcinogens and promutagens. The reactive metabolites 
generated by CYP1 enzymes are metabolized by phase II enzymes to inactive 
products (Shimada et al, 1996). Therefore, modulation of AHR function may be an 
important mechanism in preventing cancer caused by environmental carcinogens. 
We therefore examined the effect of genistein and resveratrol on the expression and 
activity of DMBA-induced CYP1 and UGT enzymes. 
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The expression of UGT1A1 is under the control of pregnane X receptor, constitutive 
androstane receptor and AhR. The XRE core sequence start at position -3309 of the 
5' flanking region of the gene (Yueh et al., 2003; Yueh et al., 2005). The 5' upstream 
region of the human CYP1A1 gene also contains several XREs mediating the Ah 
response (Morel & Barouki，1998). While for CYP1B1，two XREs have been 
identified to be critical for its induction by PAH. All the above genes are under the 
regulation of AhR and are inducible by PAH. In the current study, the effects of 
genistein and resveratrol on PAH-induced UGT1A1, CYP1A1 and CYP1B1 
expression were investigated. 
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4.2 Results 
4.2.1 Genistein and Resveratrol Reduced DMBA-induced UGT1A1, 
CYP1A1 and CYP1B1 Expression 
We demonstrated that genistein and resveratrol inhibited DMBA-induced UGT1A1 
expression in a dose-dependent manner. DMBA induced the expression of UGT1 Al 
by about 5.5 fold. Five fiM resveratrol and 5 \iM genistein reduced DMBA-induced 
UGT1A1 by about 60% and 50% respectively (Fig. 4.2 and 4.3). The expression of 
CYP1A1 and CYP1B1 was also induced by DMBA by about 116 fold and 6 fold 
respectively. One |iM resveratrol or genistein significantly reduced DMBA-induced 
CYP1A1 expression by 40% and 60% (Fig. 4.6 and 4.7), while 5 pM resveratrol or 
genistein reduced DMBA-induced CYP1B1 expression by 40% and 30% 
respectively (Fig. 4.4 and 4.5). 
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Relative Expression of UGT1A1 in Resveratrol-treated 
MCF-10A Cells 
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Fig. 4.2 Effect of resveratrol on UGT1A1 expression. MCF-10A cells were treated 
with 2.5 jiM DMBA and resveratrol and cultured for 24 h. mRNA 
expression of UGT1A1 was quantified by real-time PCR. Values are 
means 士SD, n=3. Means marked with (##) are significantly lower than 
sample treated with DMBA alone (p<0.01). 
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Relative Expression of UGT1A1 in Genistein-treated 
MCF-10A Cells 
< 6 
O 5 X T 
• 拌 
11 . •—II^•——雜“. 0 1 
二 r • . 丨 • ， • . • 
Control 0 0.1 1 5 10 
[Genistein] pM + 2.5pM DMBA 
Fig. 4.3 Effect of genistein on UGT1A1 expression. MCF-10A cells were treated 
with 2.5 jaM DMBA and genistein and cultured for 24 h. mRNA 
expression of UGT1A1 was quantified by real-time PCR. Values are 
means 士SD，n二3. Means marked with (##) are significantly lower than 
sample treated with DMBA alone (p<0.01). 
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Relative Expression of CYP1B1 in Resveratrol-treated 
MCF-10A Cells 
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Fig. 4.4 Effect of resveratrol on CYP1B1 expression. MCF-10A cells were treated 
with 2.5 |iM DMBA and resveratrol and cultured for 24 h. mRNA 
expression of CYP1B1 was quantified by real-time PCR. Values are means 
士SD, n=3. Means marked with (#) are significantly lower than sample 
treated with DMBA alone (p<0.05). 
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Relative Expression of CYP1B1 in Genistein-treated MCF-
10A Cells 
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Fig. 4.5 Effect of genistein on CYP1B1 expression. MCF-10A cells were treated 
with 2.5 }iM DMBA and genistein and cultured for 24 h. mRNA 
expression of CYP1B1 was quantified by real-time PCR. Values are means 
土SD, n=3. Means marked with (#) are significantly lower than sample 
treated with DMBA alone (p<0.05). 
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Relative Expression of CYP1A1 in Resveratrol-treated 
MCF-10A Cells 
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Fig. 4.6 Effect of resveratrol on CYP1A1 expression. MCF-10A cells were treated 
with 2.5 |iM DMBA and resveratrol and cultured for 24 h. mRNA 
expression of CYP1A1 was quantified by real-time PCR. Values are means 
士SD, n=3. Means marked with (#) are significantly lower than sample 
treated with DMBA alone (p<0.05). 
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Relative Expression of CYP1A1 in Genistein-treated 
MCF-1 OA Cells 
| : P = L , I 
j：^  I 
I 60 1 — — j S 
山 40 J ^^H ^ x # 
1 200 | - , • , I, I, il— 
Control 0 1 5 10 
[Genistein] pM + 2.5 _ DMBA 
Fig. 4.7 Effect of genistein on CYP1A1 expression. MCF-1 OA cells were treated 
with 2.5 \xM DMBA and genistein and cultured for 24 h. mRNA 
expression of CYP1A1 was quantified by real-time PCR. Values are means 
士SD，n二3. Means marked with (#) are significantly lower than sample 
treated with DMBA alone (p<0.05). 
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4.2.2 Genistein and Resveratrol Reduced the Formation of DMBA-DNA Adduct 
in MCF-10A Cells 
D M B A could intercalate D N A and causes D N A damage. In the present study, 1 JLIM 
resveratrol reduced the DNA adduct formation in MCF-10A cells by about 20%. 
Five JJ.M and 10 JJM could reduce the DNA adduction formation by 40% (Fig. 4.8). 
Fig. 4.9 showed that genistein could also reduce DMBA-DNA adduct formation in 
MCF-10A cells. One and 5 |iiM genistein could reduce DNA adduct formation by 
about 35% while 10 JIM genistein could reduce the formation by 45%. 
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Formation of DMBA-DNA Adduct in Resveratrol 
treated MCF-10A 
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Fig. 4.8 Effect of resveratrol on DMBA-DNA binding. MCF-10A cells were 
seeded in 6-well culture plates and treated with tritiated DMBA and 
genistein. After a 16 h treatment, genomic DNA was extracted and the 
DMBA-DNA lesions were determined by scintillation counting. Values are 
means 士 SD, n = 3. Means marked (#) are significantly lower than the 
cultures treated with DMBA alone (p < 0.05). 
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DMBA-DNA Adduct Formation in Genistein-treated MCF-
10A Cells 
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Fig. 4.9 Effect of genistein on DMBA-DNA binding. MCF-10A cells were seeded 
in 6-well culture plates and treated with tritiated DMBA and genistein. 
After a 16 h treatment, genomic DNA was extracted and the DMBA-DNA 
lesions were determined by scintillation counting. Values are means 士 SD, 
n = 3. Means marked (#) are significantly lower than the cultures treated 
with DMBA alone (p < 0.05). 
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4.2.3 Genistein and Resveratrol Reduced the Single Strand DNA Damage 
Generated by DMBA in MCF-10A Cells 
Fig 4.10 and 4.12 showed the images of comet assay. MCF-10A cells were treated 
with 2.5 \xM DMBA and genistein or resveratrol. Cells with single-strand DNA 
damage showed comet tails. 
Cells treated with DMBA or co-treated with 0.1 or 1 |iM of phytochemical showed 
comparable percentages of intact cells which were significantly lower than Control. 
(Fig. 4.11 and 4.13). The percentage of intact cells in DMBA co-treated with 5 \iM 
or 10 JXM genistein was similar to Control. In D M B A and 5 JIM or 10 \iM resveratrol 
co-treated MCF-10A cells, the mean percentage of intact cells was not significantly 
different from Control. 
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Fig. 4.10 Effect of resveratrol on DMBA genotoxicity in MCF-10A cells. Cells were 
seeded in 6-well culture plates and treated with 2.5 fiM DMBA and 
resveratrol. After a 72 h treatment, cells were disaggregated with 
trypsin/EDTA prior to incorporation into the comet assay as described in 
Materials and Methods. The microscopic slides were visualized with 
epifluorescence using a nikon TE2000 microscope. 
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Percentage of Undamaged Intact Cells in Resveratrol-
treated MCF-10A Cells 
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Fig. 4.11 Comet-forming activity of DMBA in resveratrol-treated MCF-10A cells. 
MCF-10A cells were seeded in 6-well culture plates and treated with 2.5 
fiM DMBA and resveratrol. After a 72 h treatment, cells were 
disaggregated with trypsin/EDTA prior to incorporation into the comet 
assay as described in Materials and Methods. Cells with fragmentated 
DNA tail were regarded as damaged cells while those which did not 
possess tail were regarded as intact cells. Values are means 士 SD, n = 3. 
Means marked (#) are significantly lower than control (p<0.005). 
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Fig. 4.12 Effect of genistein on DMBA genotoxicity in MCF-1 OA cells. Cells were 
seeded in 6-well culture plates and treated with 2.5 DMBA and 
genistein. After a 72 h treatment, cells were disaggregated with 
trypsin/EDTA prior to incorporation into the comet assay as described in 
Materials and Methods. The microscopic slides were visualized with 
epifluorescence using a nikon TE2000 microscope. 
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Percentage of Undamaged Intact Cells in Genistein-
treated MCF-10A Cells 
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Fig. 4.13 Comet-forming activity of DMBA in genistein-treated MCF-10A cells. 
MCF-10A cells were seeded in 6-well culture plates and treated with 2.5 
j^ M DMBA and genistein. After a 72 h treatment, cells were disaggregated 
with trypsin/EDTA prior to incorporation into the comet assay as described 
in Materials and Methods. Cells with fragmentated DNA tail were regarded 
as damaged cells while those which did not possess tail were regarded as 
intact cells. Values are means 土 SD, n = 3. Means marked (#) are 
significantly lower than control (p < 0.05). 
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4.2.4 Genistein and Resveratrol Reduced DMBA-induced EROD Activities 
DMBA induced EROD activity by 3-4 fold. One resveratrol significantly 
reduced DMBA-induced E R O D activity by about half. Five \xM and 10 JIM 
resveratrol further reduced the DMBA-induced EROD activity by about 62% and 
65% respectively (Fig. 4.14). 
Similar results were observed in genistein treatment. Fig. 4.15 showed that 1 JIM 
genistein reduced DMBA-induced EROD activity by about 50%. Five juM and 10 
fj,M genistein further reduced DMBA-induced EROD activity by about 65% and 75% 
respectively. 
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Fig. 4.14 Effect of resveratrol on EROD activity. MCF-10A cells were seeded in 
96-well culture plates and treated with 2 .5 |LIM D M B A and resveratrol. 
After a 24 h treatment, the cells were assayed for EROD activity. Values 
are means 士 SD, n = 3.Means marked (#) are significantly lower than the 
cultures treated with DMBA alone (p < 0.05). 
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Relative EROD Activity in Genistein Treated MCF-10A 
Cells 
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Fig. 4.15 Effect of genistein on EROD activity. MCF-10A cells were seeded in 
96-well culture plates and treated with 2.5 |iiM DMBA and genistein. After 
a 24 h treatment, the cells were assayed for EROD activity. Values are 
means 士 SD, n = 3. Means marked (#) are significantly lower than the 
cultures treated with DMBA alone (p < 0.01). 
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4.3 Discussion 
Genistein has been shown to suppress the expression and activities of 
DMBA-induced CYP1A1 and CYP1B1 enzymes in MCF-7 cells by modulating the 
XRE-dependent transactivation pathway (Chan & Leung, 2003). On the other hand, 
resveratrol has also been proven to inhibit the expression and activity of CYP1A1 
induced by benzo[a]pyrene (B[a]P) and 2,3,7,8-tetrachlorodibenzodioxin (TCDD) in 
vitro. The suppression of the trans-activity of AhR is responsible for the action of 
inhibition (Ciolino et al., 1998; Casper et al., 1999; Singh et al., 2000; Ciolino & 
Yeh，2001; Lee & Safe, 2001; Mollerup et al., 2001). Dietary administration of 
resveratrol (10 p.p.m.) causes striking reductions in DMBA-induced rat mammary 
carcinogenesis and extends the latency period of tumor development (Banerjee et al., 
2002). 
In the present study, we selected MCF-10A cells as a model to demonstrate the effect 
of genistein and resveratrol on DMBA-induced CYP1 and UGT expression and 
activities. MCF-10A cell is an immortalized cell line derived from a non-tumorigenic 
normal breast epithelium. Our results showed that genistein and resveratrol could 
inhibit DMBA-induced UGT1A1 expression in a dose-dependent manner. DMBA 
induced the expression of UGT1A1 by about 5.5 fold. Five resveratrol and 5 \xM 
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genistein significantly reduced DMBA-induced UGT1A1 by about 60% and 50% 
respectively (Fig. 4.2 and 4.3). The expression of CYP1A1 and CYP1B1 was also 
induced by DMBA by about 116 fold and 6 fold respectively. One |iiM resveratrol 
and 1 JIM genistein significantly reduced DMBA-induced CYP1A1 expression by 
40% and 66% (Fig. 4.6 and 4.7)，while 5 JJM resveratrol and 5 |iM genistein reduced 
DMBA-induced CYP1B1 expression by 40% and 30% respectively (Fig. 4.4 and 
4.5). It has been demonstrated that genistein and resveratrol inhibit PAH-induced 
CYP1A1 and CYP1B1 expression by modulating the XRE-dependent transactivation 
pathway in other cell lines (Ciolino et al., 1998; Casper et al., 1999; Singh et al, 
2000; Ciolino & Yeh，2001; Lee & Safe，2001; Mollerup et al., 2001; Chan & Leung， 
2003), therefore the inhibition of DMBA-induced CYP1A1 and CYP1B1 expression 
in the current study is likely related to the XRE transactivation pathway. 
Previous studies have demonstrated UGT1A1 expression is mediated by AhR (Yueh 
et al., 2003; Yueh et al., 2005). Therefore the induction of UGT1A1 by DMBA 
observed in the current study could be regulated by the XRE transactivation pathway. 
However, few investigations have undertaken on the effects of genistein and 
resveratrol on PAH-induced UGT1A1 expression. Some studies focus on the effects 
of isoflavones on the enzyme activity of UGT1A1. Pfeiffer et al (2005) have shown 
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that genistein inhibits the glucuronidation activity of UGT1A1. On the contrary, Sun 
et al. (1998) have found that UGT activity is induced by 5 fiM genistein in LNCaP 
cells. The contradictory results may be caused by assay variations at the protein and 
cell levels. Our results showed that both genistein and resveratrol inhibited 
DMBA-induced UGT1A1 expression in a dose-dependent manner. The actual 
mechanism involved was not determined but we speculated that such regulation was 
similar to those of CYP1A1 and CYP1B1. CYP1A1, CYP1B1 and UGT1A1 all 
contain XRE in their promoter region. Genistein and resveratrol might inhibit their 
expression by directly interact with AhR, and changed its 3-D structure. It was also 
possible that genistein and resveratrol competed with PAH for the active site. 
Another possible reason was that genistein and resveratrol prevented the 
ligand-activated AhR dimmer from interacting with the XRE in the promoter region. 
The actual mechanism can be confirmed by electromobility gel shift assay (Yueh et 
al, 2005) or reporter gene assay (Chan & Leung，2003). 
Genistein and resveratrol reduced DMBA-induced EROD activity (Fig. 4.14 and 
4.15). The reduction might be caused by decreased expression of CYP1A1 and 
CYP1B1 as described above. Or the phytochemicals inhibited the enzyme activity of 
CYP1A1 and CYP1B1. Previous studies have demonstrated that genistein and 
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resveratrol could inhibit CYP1A1 and CYP1B1 activities (Shertzer et al., 1999; Chen 
et al” 2004). 
DMBA-induced CYP1A1 and CYP1B1 were reduced by genistein and resveratrol. 
This should have positive effects on the prevention of cancer because less reactive 
epoxide metabolites would be generated. However, UGT1A1, which transforms 
reactive metabolites generated by phase I enzymes to inactive products, was 
suppressed at the same time. In this case, it appeared that the positive effects caused 
by suppression of CYP1A1 and CYP1B1 were out-weighed by suppressing UGT1A1. 
Therefore we investigated the effect of genistein and resveratrol on DNA damage 
generated by DMBA by measuring the formation of DNA adduct and single cell gel 
electrophoresis. 
The present study showed that genistein or resveratrol reduced DMBA-DNA adduct 
formation and the underlying mechanism might be attributed to its interruption on 
DMBA metabolism. One |iiM genistein or 1 |iiM resveratrol could significantly 
reduce DMBA-DNA adduct formation (Fig. 4.8 and 4.9). Comet assay enables us to 
detect single strand damage with high sensitivity. Cells with single-strand DNA 
damage will show a comet tail. As shown in Fig 4.10 and 4.11, cells co-treated with 
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DMBA and 0.1 or 1 pM of phytochemical showed comparable percentage of intact 
cells. At these concentrations, the phytochemicals could not protect the cells from 
single-strand DNA damage generated by 2.5 \iM DMBA. Five [iM genistein or 
resveratrol offered a protective effect towards DNA damage as the percentage of 
intact cells was similar to Control. This protective effect might also be contributed by 
their interruption on DMBA metabolism. Since DMBA-induced CYP1A1 and 
CYP1B1 was suppressed by resveratrol and genistein, reduced reactive metabolites 
and decreased DNA damage were produced. Although UGT1A1 was also suppressed, 
the suppression of UGT1A1 seemed not a significant contributor to the DNA damage. 
We might conclude that the protective mechanism against DMBA initiation offered 
by genistein and resveratrol was independent of UGT1A1. 
In summary, the current study demonstrated that genistein and resveratrol suppressed 
the expression of UGT1A1, CYP1A1 and CYP1B1 induced by DMBA, and DNA 
damage was reduced by the phytochemicals. The result implied that the suppressions 
of CYP1A1 and CYP1B1 contributed to the reduction of DNA damage. Besides, 
UGT1A1 did not seem to be involved in the protection of the two phytochemicals 
against xenobiotic assault on DNA. 
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CHAPTER 5 EFFECTS OF U G T 1 A 1 ON CANCER DRUG 
TREATMENT 
5.1 Introduction 
UGTs catalyze the transfer of the glucuronosyl group from uridine 
5'-diphospho-glucuronic acid (UDPGA) to substrate molecules that contain oxygen, 
nitrogen, sulfur or carboxyl functional groups. It is an important step in the body's 
elimination of foreign substances (such as drugs) and endogenous substances 
(including toxins) (Guillemette et al., 2000). Therefore we would like to investigate 
if UGT1A1 expression will affect cancer drug treatment. 
UGT1A1 enzyme has been reported to catalyze the glucuronidation of SN-38，which 
is the active metabolite of a cancer drug, irinotecan and as a result improve the 
therapeutic index of irinotecan (Iyer et al., 1998). It is possible for UGT1A1 enzyme 
to affect the effectivness of other drugs. In the present study, we investigated the 
effects of UGT1A1 enzyme on the effectiveness of several commonly used cancer 
drugs, paclitaxel, vincristine, methotrexate and doxorubicin. 
Paclitaxel (Taxol®) is a drug commonly used to treat patients with cancer, such as 
lung, ovarian and breast cancer. It acts by interfering microtubule growth. Taxol® 
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binds to the (3 subunit of tubulin and prevent the mircrotubule from disassembling, 
and thereby preventing normal cell division and arrest the cell cycle at the G2/M 
phase (Blagosklonny & Fojo, 1999). 
Vincristine (VCR) is commonly used in treatment of cancer such as lymphomas and 
breast cancer. Vincristine binds to tubulin dimers causing disassembly of 
microtubule structures. Disruption of the microtubules arrests mitosis in metaphase 
(Jordan et al, 1998). 
Methotrexate (MTX) is used to treat cancer such as breast, head and neck, lung, 
blood, and bone cancer. It inhibits growth of cancer cells by inhibiting the synthesis 
of nucleoside thymidine. Synthesis of DNA, RNA, thymidylates, and proteins are 
inhibited (Schilsky, 1996). 
Doxorubicin (DOX) is used to treat cancer such as breast cancer and ovarian cancer. 
Doxorubicin acts by binding to DNA where it can inhibit the progression of the 
enzyme topoisomerase II. Doxorubicin stabilizes the topoisomerase II complex and 
thereby the replication process is terminated (Gewirtz, 1999). 
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The cancer drugs affect the cell cycle. Cell cycle is divided into four phases, 
including the Gi phase, S phase, G2 phase and M phase (Fig. 5.1). Cell cycle 
progression is regulated by a family of protein kinases with which activities change 
in response to cellular signals. These kinases are heterodimers with a regulatory 
subunit, cyclin, and a catalytic subunit, cyclin-dependent protein kinase (CDK). 
CDKs are active only in the presence of cyclin. Activated CDKs phosphorylate target 
proteins so as to activate or inactivate them and the cell can enter the next phase of 
the cell cycle. Different cyclin-CDK combinations determine the downstream target 
proteins. 
Cell cycle progression is monitored and will be stopped if extensive DNA damage 
occurs or other important events cannot occur properly. These checkpoints ensure the 
cell will divide only when it has completed all molecular events properly. The tumor 
suppressor gene p53 is required for checkpoint control during cell cycle progression. 
Once DNA replication cannot occur properly or extensive DNA damage exists, p53 
will trigger apoptosis. Apoptosis is a complicated caspase cascade. The family of 
Bcl-2 related proteins constitutes one of the most biologically relevant classes of 
apoptosis regulators acting at the effector stage (Kroemer, 1997; Reed 1997). Bcl-2 
is an anti-apoptotic protein. In the cytosol, binding of cytochrome c to the adapter 
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protein CED-4 promotes activation of a caspase cascade and thus apoptosis occurs. 
Bcl-2 blocks the release of cytochrome c in to cytosol and thereby inhibiting 
apoptosis. Bax is a pro-apoptotic protein which promotes release of cytochrome c 
into the cytosol and apoptosis. 
To investigate the potential adversed effects of UGT1A1 on cancer drug therapy, we 
employed a model of MCF-7 cells over-expressing UGT1A1. We analyzed the cell 
cycle of the cells treated with cancer drugs, and determined the levels of Bcl-2 and 
Bax protein expression. 
r _ P H A S E 
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Fig 5.1 The phases of the cell cycle (adapted from Molecular Biology of the Cell, 
4th edition, 2002) 
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5.2 Results 
5.2.1 Cell Proliferation Experiment 
Vector-transfected (MCF-7contro|), UGT1A1-transfected (MCF-7UGTIAI) and wild 
type MCF-7 cells were treated with paclitaxel, DOX, VCR and MTX for 5 days. A 
5-day treatment enabled us to have a clearer view on cell survival. In MCF-7controi 
and MCF-7 cells, the drugs inhibited cell growth in a dose-dependent manner. In 
MCF-7UGTIAI cells, DOX and MTX treatment showed dose-dependent growth 
inhibition similar to that in the MCF-7controi and the wild type cells. Treatment with 
paclitaxel and VCR, however, resulted in lesser inhibition. As presented in Fig. 5.2 
and 5.3, paclitaxel- or VCR- treated MCF-7UGTIAI cells had higher percentage of cell 
survival than that observed in MCF-7controi cells or MCF-7 cells under the same 
treatment. In contrast, growth inhibition induced by DOX and MTX was similar in 
all cell types tested. 
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Fig. 5.2 Percentage of survival in MCF-7UGTIAI , MCF-7co咖丨 and wild type MCF-7 
cells after a 5-day exposure to various concentrations of paclitaxel. Values 
are means 土 SEM, n=4. 
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Fig. 5.3 Percentage of survival in MCF-7UGTIAI, MCF-7COntroi and wild type MCF-7 
cells after a 5-day exposure to various concentrations of doxorubicin. 
Values are means 士 SEM, n=4. 
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Fig. 5 . 4 Percentage of survival in MCF-7UGTIAI, M C F - 7 C O n t r o i and wild type M C F - 7 
cells after a 5-day exposure to various concentrations of vincristine. Values 
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Fig. 5.5 Percentage of survival in MCF-7UGTIAI, MCF-7COntroi and wild type MCF-7 
cells after a 5-day exposure to various concentrations of methotrexate. 
Values are means 士 SEM, n=4. 
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5.2.2 Expression of Bcl-2 and Bax proteins in Paclitaxel- or VCR-treated MCF-7, 
MCF-7 c o n troi and MCF-7UGTIAI cells 
To define the molecular mechanism by which over-expression of UGT1A1 protects 
breast cancer cells against apoptosis induced by the tubulin-binding agents, the 
expression of Bcl-2 family proteins was evaluated by Western blot analysis. In 
paclitaxel- or VCR-treated MCF-7UGTIAI cells, Bcl-2 protein expression was reduced 
in a does-dependent manner. Besides, Bcl-2 was over-expressed in MCF-7UGTIAI 
cells when compared with MCF-7 and MCF-7control cells (Fig. 5.6 and 5.7). In 
contrast, the expression of Bax protein showed no significant difference upon 
paclitaxel or VCR treatment between the cell lines, either overall or separately by 
dose (Fig. 5.6 and 5.7). 
In DOX- or MTX- treated MCF-7UGTIAI cells, Bcl-2 was over-expressed but showed 
no significant difference by dose. Bax expression showed a dose-dependent increase 
in DOX-treated cells; but it showed no significant change in MTX-treated cells (Fig. 
5.8 and 5.9). 
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Fig. 5.6 Immunoblot analysis of Bcl-2 and Bax expression in paclitaxel-treated 
M C F - 7 , M C F - 7 c o n t r o i and MCF-7UGTIAI cells. Cells were treated with 
vehicle (DMSO), 0.001，0.01 and 1 \M paclitaxel for 24 h. Cells were then 
harvested, and cell extract was prepared and subjected to Western blot 
analysis. 
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Fig. 5.7 Immunoblot analysis of Bcl-2 and Bax expression in VCR-treated MCF-7, 
MCF-7controi and MCF-7UGTIAI cells. Cells were treated with vehicle 
(DMSO), 0.002, 0.006 and 0.01 从M VCR for 24 h. Cells were then 
harvested, and cell extract was prepared and subjected to Western blot 
analysis. 
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Fig. 5.8 Immunoblot analysis of Bcl-2 and Bax expression in MTX-treated MCF-7, 
MCF-7controi and MCF-7UGTIAI cells. Cells were treated with vehicle 
(DMSO), 0.1, 0.2 and 0.4 i^M MTX for 24 h. Cells were then harvested, 
and cell extract was prepared and subjected to Western blot analysis. 
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Fig. 5.9 Immunoblot analysis of Bcl-2 and Bax expression in DOX-treated MCF-7, 
MCF-7controi and MCF-7UGTIAI cells. Cells were treated with vehicle 
(DMSO), 0.1, 0.2 and 0.4 i^M DOX for 24 h. Cells were then harvested, 
and cell extract was prepared and subjected to Western blot analysis. 
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5.2.3 Flow Cytometric Analysis of Cell Cycle Phase Distribution in Paclitaxel- or 
VCR-treated MCF-7 cells 
To establish general characteristics of the cell cycle response to the tubulin-binding 
agents, MCF-7 cells were exposed to various concentrations of paclitaxel or VCR. 
The wild type or MCF-7C0ntr0i cells treated with paclitaxel or VCR were arrested in 
G2/M phase as compared to vehicle treatment (Table 5.1，5.3, 5.4 and 5.6). In 
contrast, over-expression of UGT1A1 in MCF-7 cells inhibited paclitaxel- or 
VCR-induced cell cycle arrest as manifested by a reduced percentage of G2/M arrest 
of living cells (38.89% and 36.59%) as compared to 26.43% and 22.51% in vehicle 
treatment (Table 5.2 and 5.5). 
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Fig. 5.10 Flow cytometric analysis of cell cycle phase distribution of 
paclitaxel-treated MCF-7controi cells. Cells were treated with (A) vehicle 
(DMSO), (B) 0.001 \M, (C) 0.01 i^M and (D) 0.1 [iM for 2 days, fixed and 
nuclear DNA was labeled with propidium iodide. Cell cycle phase 
distribution was determined by single label flow cytometery. 
Paclitaxel/pM 0 0.001 0.01 0.1 
SubG1 1.8181818 1.7665212 4.5091324 2.8899134 
G0/G1 42.885835 40.310737 20.239726 19.217362 
S 6.8816068 7.9599872 6.6210046 6.3758012 
G2/M 31.807611 31.690965 47.888128 50.545373 
Table 5.1 Cell cycle phase distribution in paclitaxel-treated MCF-7�ntroi cells‘ 
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Fig. 5.11 Flow cytometric analysis of cell cycle phase distribution of 
paclitaxel-treated MCF-7UGTIAI cells. Cells were treated with (A) vehicle 
(DMSO), (B) 0.001 |iM, (C) 0.01 i^M and (D) 0.1 \M for 2 days, fixed and 
nuclear DNA was labeled with propidium iodide. Cell cycle phase 
distribution was determined by single label flow cytometery. 
Paclitaxei/|jM 0 0.001 0.01 0.1 
Sub 01 3.0289483 3.2926968 5.8790404 3.7858117 
G0/G1 35.676763 44.286203 28.066224 23.465211 
S 5.7896502 3.6686795 11.037279 7.7535243 
G2/M 26.433441 26.307394 30.555243 38.892678 
Table 5.2 Cell cycle phase distribution in paclitaxel-treated MCF - 7 UGTIA I cells. 
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Fig. 5.12 Flow cytometric analysis of cell cycle phase distribution of 
paclitaxel-treated MCF-7 cells. Cells were treated with (A) vehicle 
(DMSO), (B) 0.001 \iU, (C) 0.01 i^M and (D) 0.1 \xM for 2 days, fixed and 
nuclear DNA was labeled with propidium iodide. Cell cycle phase 
distribution was determined by single label flow cytometery. 
Paclitaxel/pM 0 0.001 0.01 0.1 
SubG1 5.9838275 1.786258 14.160915 6.4458838 
G0/G1 44.442049 25.109104 14.19327 10.185959 
S 5.9191375 2.5068507 6.7083693 5.4011701 
G2/M 20.086253 21.455394 35.903796 53.792311 
Table 5.2 Cell cycle phase distribution in paclitaxel-treated MCF-7UGTIAI cells. 
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Fig. 5.13 Flow cytometric analysis of cell cycle phase distribution of VCR-treated 
MCF-7controi cells. Cells were treated with (A) vehicle (DMSO), (B) 0.002 
fiM，(C) 0.006 [M and (D) 0.01 t^M for 2 days, fixed and nuclear DNA 
was labeled with propidium iodide. Cell cycle phase distribution was 
determined by single label flow cytometery. 
VCR/|JM 0 0.002 0.006 0.01 
SubG1 1.5015015 4.5149551 8.2029807 9.7070506 
G0/G1 37.548263 36.017286 18.6353 17.204568 
S 4.9442299 6.3573297 7.3161719 7.9692155 
G2/M 32.378807 35.551006 48.799113 47.095333 
Table 5.2 Cell cycle phase distribution in paclitaxel-treated MCF-7UG tiAI cells. 
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Fig. 5.14 Flow cytometric analysis of cell cycle phase distribution of VCR-treated 
MCF-7UGTIAI cells. Cells were treated with (A) vehicle ( D M S O ) , (B) 0.002 
JIM, (C) 0.006 JIM and (D) 0.01 |iM for 2 days, fixed and nuclear DNA 
was labeled with propidium iodide. Cell cycle phase distribution was 
determined by single label flow cytometery. 
V C R / P M 0 0 . 0 0 2 0 . 0 0 6 0 .01 
Sub G1 3.2467532 5.0610032 6.3701513 5.4667884 
G0/G1 39.229736 35.314053 26.083494 30.723579 
S 9.5499328 8.5969272 7.6669321 6.4597124 
G2/M 22.514554 28.15183 33.966557 36.58982 
Table 5.2 Cell cycle phase distribution in paclitaxel-treated M C F - 7 U G T I A I cells. 
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Fig. 5.15 Flow cytometric analysis of cell cycle phase distribution of VCR-treated 
MCF-7 cells. Cells were treated with (A) vehicle (DMSO), (B) 0.002 pM, 
(C) 0.006 \M and (D) 0.01 |iM for 2 days, fixed and nuclear DNA was 
labeled with propidium iodide. Cell cycle phase distribution was 
determined by single label flow cytometery. 
VCR/pM 0 0.002 0.006 0.01 
Sub G1 1.0071942 2.7135569 4.3861632 7.4237251 
G0/G1 26.18705 24.639097 12.887181 14.935566 
S 2.9393628 3.6253121 3.6174542 3.1941844 
G2/M 22.970195 33.528709 43.138142 40.863531 
Table 5.2 Cell cycle phase distribution in paclitaxel-treated MCF-7UGTIAI cells. 
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5.3 Discussion 
Among the four drugs tested, paclitaxel and VCR were less effective in inducing cell 
death in MCF-7UGTIAI cells while DOX and M T X remained effective. The IC50 of 
paclitaxel and VCR was higher in MCF-7UGTIAI cells then in M C F - 7 cells or MCF-7 
cells transfected with vector. These results implied that over-expressing UGT1A1 in 
MCF-7 cells might make the cells become resistant to paclitaxel or VCR treatment. 
The Bcl-2 and Bax levels were determined by Western blot. We found that Bcl-2 was 
over-expressed in MCF-7UGTIAI cells when compared with M C F - 7 and MCF-7controi 
cells, while expression of Bax was similar in the three cell lines. In paclitaxel- or 
VCR-treated MCF-7UGTIAI cells, Bcl-2 expression showed a dose-dependent decease . 
while Bax expression did not change. As Bcl-2 is an anti-apoptotic protein, a high 
level expression in MCF-7UGTIAI cells might be one of the mechanisms that inhibited 
apoptosis induced by paclitaxel and VCR. Paclitaxel and VCR induce Bcl-2 
phosphorylation (Haldar et al, 1998). A decrease in Bcl-2 activity promoted 
apoptosis. Therefore there was a higher percentage of cells arrested in G2/M phase 
when the concentration of paclitaxel or VCR was higher. 
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However, the over-expression of Bcl-2 did not protect the MCF-7UGTIAI cells from 
apoptosis induced by DOX and MTX. As shown in Fig. 5.8 and 5.9, the Bcl-2 
expression level showed no significant difference by dose. This implied that there 
could be a Bcl-2 independent mechanism that protects the MCF-7UGTIAI cells from 
apoptosis. Over-expression of Bcl-2 has been demonstrated to offer resistance to 
DOX in MCF-7 cells (Davis et al., 2003); however, in the current study, the 
over-expression of Bcl-2 in MCF-7UGTIAI cells did not have resistance towards DOX 
therapy. This implied that over-expression of UGT1A1 had mechanisms to abrogate 
the effect of over-expressing Bcl-2. 
In DOX-treated MCF-7, M C F - 7 C O _ I and MCF-7UGTIAI cells, the expression level of 
Bax protein showed a dose-dependent increase. This might account for the cell death 
as Bax is a pro-apoptotic protein. On the contrary, the expression of Bax protein in 
MTX-treated cells did not show significant difference. 
The differences in response of.MCF-7uGTiAi cells towards the four tested drugs may 
be attributed to their modes of action. Paclitaxel and VCR are tubulin-binding agents 
while DOX and MTX are DNA-damaging agents. The mechanism of how 
over-expression of UGT1A1 lowers the effectiveness of paclitaxel and VCR was 
i l l 
unclear. A higher level of Bcl-2 might be just one of the mechanisms responsible for 
offering the resistance towards paclitaxel and VCR treatment. The apoptotic pathway 
is a complicated caspase cascade. To have a clear view of how UGT1A1 interacts 
with the tubulin-binding agents, further investigations on the molecular pathway 
should be performed. For example, we can investigate if UGT1A1 will affect the 
tubulin network by in situ staining of microtubules. Or tubulin polymerization can be 
studied. 
Cell cycle progression is controlled by several different cyclin-dependent protein 
kinases (CDKs) regulatory mechanisms (Stewart et al., 2003). Binding with the 
catalytic subunit of cyclin activates Cdk and promotes cell growth, whereas Cdk 
inhibitor inactivates Cdk/cyclin complexes and reduces cell growth, and eventually 
leads to cell death. Microtubules damage induced by tubulin-binding agents activates 
the spindle-assembly checkpoint. Degradation of cyclin B is blocked, and mitotic 
arrest results (Hagting et al, 1998). Since cell cycle arrest in G2/M phase induced by 
the tubulin-binding agents was decreased by over-expressing UGT1A1 in the current 
study, the expression level of cyclin B as well as other related kinase activities might 
have reduced. The expression of cyclin B and other cell cycle regulatory proteins, 
such as p53 and p21, should be determined in future study. 
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In summary, UGT1A1 lowered the therapeutic potency of paclitaxel and vincristine 
but the underlying mechanism was not clear. The results implied that UGT1A1 
polymorphism might be a confounding factor in chemotherapy. 
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CHAPTER 6 SUMMARY 
In this research, the effects of over-expression of UGT1A1 and CYP1A1 against 
xenobiotic assault were investigated. The results indicated that an elevated level of 
UGT1A1 could conjugate and reduce the amount of free estrogen, thus abolished its 
effect on cell proliferation and regression of estrogen receptor expression. Besides, 
UGT1A1 could detoxify DMBA, thereby reduced the ultimate DNA damage. In 
contrast, over-expression ofCYPlAl increased the DNA damage caused by estradiol 
and DMBA. 
UGT1A1, CYP1A1 and CYP1B1 are susceptible genes for breast cancer, and 
genistein and resveratrol are potential protective non-nutrients against breast cancer. 
We were interested to examine this diet and gene interaction. Our result 
demonstrated that genistein and resveratrol could suppress DMBA-induced UGT1A1, 
CYP1A1 and CYP1B1 expression. Suppression of CYP1A1 or CYP1B1 could be 
beneficial but a reduction of UGT1A1 might not be desirable. However, results of 
comet assay and DMBA-DNA adduct formation showed that the DMBA-treated 
cells were still protected by genistein and resveratrol, indicating that the suppression 
of UGT1A1 was not significant. We could conclude that the protective mechanism 
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against DMBA tumor initiation offered by genistein and resveratrol was independent 
o fUGTlAl . 
UGT1A1 is also a major Phase II enzyme responsible for metabolizing drugs and 
xenobiotics. We also asked if an elevated level of UGT1A1 would affect cancer drug 
therapy. Our results demonstrated that an elevated level of UGT1A1 lowered the 
effectiveness of tubulin-binding agents but not DNA-damaging agents. The 
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